

1.

Profiles
December 31, 2015

Alan F. Schatzberg, MD
LIST OF PUBLICATIONS

Abstracts

- A-1. Cole JO, Schatzberg AF. Technology: Modern management of affective disease. IV World Congress of Psychiatry, 1977:113.
- A-2. Schildkraut JJ, Orsulak PJ, Gudeman JE, Schatzberg AF, Rohde WA, LaBrie RA, Cahill JF, Cole JO. Catecholamine metabolism in depressive disorders: Implications for classification and treatment (I). IV World Congress of Psychiatry, 1977:112.
- A-3. Schatzberg AF, Schildkraut JJ, Cole JO, Orsulak PJ, Gudeman JE, Rohde WA, LaBrie RA, Cahill JF: Catecholamine metabolism in depressive disorders: Implications for classification and treatment (II). IV World Congress of Psychiatry, 1977:112.
- A-4. Schatzberg AF, Schildkraut JJ. Toward a biological and clinical classification system for depressive disorders. IV World Congress of Psychiatry, 1977:37.
- A-5. Schatzberg AF. Treatment-resistant depression: Overview and patient characteristics. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1978:166.
- A-6. Schatzberg AF, Rosenbaum AH, Cole JO, Rohde WH, Orsulak PJ, Schildkraut JJ. Preliminary studies of maprotiline. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1979:168.
- A-7. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Biochemical tests in psychiatric diagnosis. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1979:167.
- A-8. Schatzberg AF Cole JO, Cohen B, Altesman RI, Sniffen C. Intolerance to antidepressant therapy. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1979:315.
- A-9. Mirin SM, Schatzberg AF, Creasey DE. Psychiatric sequelae of tricyclic withdrawal. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1980:314.
- A-10. Schatzberg AF, Cole JO, Orsulak PJ, Rosenbaum J, Schildkraut JJ. The clinical laboratory in psychiatric practice. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1980:178.

- A-11. Gudeman JE, Schatzberg AF, Orsulak PJ, Samson JA, Cole JO, Schildkraut JJ. MAO activity and clinical symptoms in depressions. Society of Biological Psychiatry Annual Mtg, 1980.
- A-12. Rosenbaum AH, Maruta T, Schatzberg AF, Orsulak PJ, Schildkraut JJ. Urinary free cortisol and MHPG levels in anxious patients and normal controls. Abstract Book, Society of Biological Psychiatry 36th Annual Mtg, 1981:78.
- A-13. Schatzberg AF. Biochemical heterogeneity of depressive disorders. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1982:154.
- A-14. Schatzberg AF, Orsulak PJ, Cole JO, Schildkraut JJ. Biochemical heterogeneity of unipolar depressions. Abstracts, Volume II, Collegium Internationale Neuropsychopharmacologicum, 13th CINP Congress, 1982:643.
- A-15. Cole JO, Schatzberg AF. Antidepressant drug therapy. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1983:7.
- A-16. Schatzberg AF, Cole JO, Duffy FH. Brain imaging in atypical depressions. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1983:29.
- A-17. Schildkraut JJ, Schatzberg AF, Cole JO, Orsulak PJ. D-type scores in depressive disorders. Continuing Medical Education Syllabus and Scientific proceedings in Summary Form Am Psych Assoc Annual Mtg, 1983:86.
- A-18. Rothschild AF, Schatzberg AF, Langlais PJ, Bird ED, Cole JO. Dexamethasone increases plasma dopamine. New Research Abstracts, Am Psych Assoc Annual Mtg, 1983:NR26.
- A-19. Schatzberg AF, Rothschild AJ, Schildkraut JJ, Orsulak PJ. Platelet monoamine oxidase and dexamethasone suppression test results in depressed patients. New Research Abstracts, Am Psych Assoc Annual Mtg, 1983:NR27.
- A-20. Schatzberg AF, Rothschild AJ, Sheehan DV. Biological studies of anxious patients. Abstracts of VII World Congress of Psychiatry, S1068, 1983:232.
- A-21. Schatzberg AF, Elliott GR, Duffy FH. Use of computer enhanced EEG in the assessment of refractory depression. Abstracts of the VII World Congress of Psychiatry, S532, 1983:128.
- A-22. Schatzberg AF, Rothschild AJ, Bond TC, Schildkraut JJ, Cole JO. The dexamethasone suppression test (DST) in psychotic and nonpsychotic depressed patients. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1983:15.

A-23. Schatzberg AF, Rothschild AJ, Langlais PJ, Cole JO, Bird ED. Dexamethasone elevates dopamine in human plasma and rat brain. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1983:16.

A-24. Dessain EC, Schatzberg AF, Wood BT, Cole JO. Seizures on maprotiline. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1983:105.

A-25. Schatzberg AF. Discriminacion biologica entre panico y depresion. Resumen del Simposio Conjunto entre el Instituto Mexicano de Psiquiatria y el Hospital McLean, Salud Mental, 1983; 6:68.

A-26. Schatzberg AF. El mapeo de la actividad electrica del cerebra (BEAM) de enfermos deprimidos. Resumen del Simposio Conjunto entre el Instituto Mexicano de Psiquiatria y el Hospital McLean, Salud Mental, 1983; 6:72.

A-27. Schildkraut JJ, Schatzberg AF, Mooney JJ, Orsulak PJ. Depressive disorders and the emerging field of psychiatric chemistry. Continuing Medical Education Syllabus and Scientific Proceeding in Summary Form, Am Psych Assoc Annual Mtg, 1984:6.

A-28. Schatzberg AF, Sheehan D, Rosenbaum AH. Differentiating anxiety from depressive disorders. Continuing Medical Education Syllabus and Scientific proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1984:25.

A-29. Schatzberg AF, Elliott G, Duffy FH, Woods BT, Cole JO. BEAM studies in atypical and refractory depression. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1984:68.

A-30. Schatzberg AF Rothschild AJ, Rosenbaum AH, Bond TC, Cole JO. DST results in patients with psychotic depression. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1984:88.

A-31. Rothschild AJ, Schatzberg AF, Langlais PJ, Cole JO, Bird ED. Dexamethasone elevates dopamine in rats and humans. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1984:89.

A-32. Samson J, Gudeman JE, Kizuka PP, Schatzberg AF, Cole JO, Schildkraut JJ. Platelet MAO activity in subtypes of depressions. New Research Abstracts, Am Psych Assoc Annual Mtg, 1984:NR63.

A-33. Mooney JJ, Schatzberg AF, Cole JO, Kizuka PP Schildkraut JJ. Depressions and receptor-adenylate cyclase linkage. New Research Abstracts, Am Psych Assoc Annual Mtg, 1984:NR64.

A-34. Schatzberg AF, Rothschild AJ, Langlais PJ, Cole JO, Bird ED. Effects of dexamethasone on monoamine and metabolite levels in rat brain and human plasma. Book of Abstracts, Colegium International Neuropsychopharmacologicum, 14th CINP Congress, 1984:41.

A-35. Rothschild AJ, Schatzberg AF, Langlais PJ, Cole JO, Bird ED. Effects of dexamethasone on monoamine and metabolite levels in rat brain and human plasma. Book of Abstracts, Collegium Internationale Neuropsychopharmacologicum, 14th CINP Congress, 1984:60.

A-36. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Seizures on maprotiline. Book of Abstracts, Collegium Internationale Neuropsychopharmacologicum 14th CINP Congress, 1984:756.

A-37. Bond TC, Rothschild AJ, Lerbinger JE, Schatzberg AF. Increased familial prevalence of affective disorder in depressed patients with markedly elevated postdexamethasone cortisol levels. Book of Abstracts, Collegium Internationale Neuropsychopharmacologicum, 14th CINP Congress, 1984:787.

A-38. Rothschild AJ, Schatzberg AF, Langlais PJ, Miller M, Cole JO. Plasma cortisol and dopamine levels in psychotic and nonpsychotic depressed patients. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1984:123.

A-39. Cole JO, Schatzberg AF, Salomon M, Dessain EC. Antidepressant use in the cognitively impaired. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:28.

A-40. Schatzberg AF, Rosenbaum AH, Cole JO, Schildkraut JJ. MHPG and the heterogeneity of unipolar depression. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:65.

A-41. Cole JO, Liptzin B, Dessain EC, Schatzberg AF, Salomon M, Lerbinger JE. Imipramine and trimipramine in geriatric depression. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:68.

A-42. Schatzberg AF. Treatment of chronic anxiety: Primary objectives. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:87.

A-43. Schatzberg AF, Cole JO, Elliott GR. Recent studies on treatment resistant depression. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:33.

A-44. Schatzberg AF, Rosenbaum AH, Schildkraut JJ. Depression: Catecholamine-cortisol relationships. Continuing Medical Education Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1985:138.

A-45. Bond TC, Rothschild AJ, Lerbinger JE, Schatzberg AF. Depressive subtypes and ranges of DST response. New Research Abstracts, Am Psych Assoc Annual Mtg, 1985:NR 93.

A-46. Schatzberg AF. Delusional depression. Abstracts of IVth World Congress of Biological Psychiatry, 1985:37.

- A-47. Bond TC, Rothschild AJ, Lerbinger JE, Schatzberg AF. DST ranges and delusional depression. Abstracts of IVth World Congress of Biological Psychiatry, 1985:37.
- A-48. Rothschild AJ, Schatzberg AF, Langlais PJ. Corticosteroid/dopamine interactions in psychotic and nonpsychotic depressed patients. Abstracts of IVth World Congress of Biological Psychiatry, 1985:38.
- A-49. Schatzberg AF. Antidepressants in the treatment of alcohol and drug abuse. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1985:33.
- A-50. Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Cole JO. Corticosteroid/dopamine interactions in rats, normal controls, and psychotic depression. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1985:83.
- A-51. Schatzberg AF, Rothschild AJ, Schildkraut JJ, Cole JO. Increased cortisol and catecholamine activity. CME Syllabus, Am Psych Assoc Annual Mtg, 1986:73.
- A-52. Schatzberg AF. Treatment of anxiety: Goals and alternatives. CME Syllabus, Am Psych Assoc Annual Mtg, 1986:111.
- A-53. Schatzberg AF Rothschild AJ, Bond TC, Cole JO. DST response in delusional depression. CME Syllabus, Am Psych Assoc Annual Mtg, 1986:176.
- A-54. Rothschild AJ, Schatzberg AF, Langlais PJ Lerbinger JE, Cole JO. Steroid/amine interaction in delusional depression. CME Syllabus, Am Psych Assoc Annual Mtg, 1986:176.
- A-55. Schatzberg AF, Dessain EC, Cole JO, Duffy FH. BEAM in psychiatry: Emphasis on the elderly. CME Syllabus, Am Psych Assoc Annual Mtg, 1986:197.
- A-56. Mooney JJ, Schildkraut JJ, Schatzberg AF, Gerson B, Pappalardo K, Cole JO. Postreceptor regulation of adenylate cyclase of NE. New Research Abstracts, Am Psych Assoc Annual Mtg, 1986:NR 165.
- A-57. Schildkraut JJ, Schatzberg AF, Mooney JJ, Gerson B, Samson JA, Cole JO. D-type scores and responses to antidepressants. New Research Abstracts, Am Psych Assoc Annual Mtg, 1986:NR 124.
- A-58. Dessain EC, Cole JO, Schatzberg AF, Salomon M. Trimipramine versus imipramine in the elderly. New Research Abstracts, Am Psych Assoc Annual Mtg, 1986:NR 98.
- A-59. Dessain EC, Cole JO, Schatzberg AF, McNiff ME, Branconnier RJ. Differential orthostatic hypotensive effects of imipramine and trimipramine in the aged. CPT Book of Abstracts, 3rd World Conference on Clinical Pharmacologic Therapeutics, Stockholm, Sweden, 1986:281.

A-60. Schatzberg AF, Rothschild AJ. Biology of delusional (psychotic) depression. Regional Meeting of the World Psychiatric Association, Book of Abstracts, 1986:170.

A-61. Schatzberg AF. Abnormalities of epinephrine in psychiatric illness. Abstracts of Panels and Posters. 25th Annual Mtg of the American College of Neuropsychopharmacology, 1986:91.

A-62. Schatzberg AF, Rothschild AJ. The role of dopaminergic systems in psychotic depression. Abstracts, The New York Academy of Sciences Conference on the Mesocorticolimbic Dopamine System, May 4-6, 1987, No. 38.

A-63. Schatzberg AF. Somatic treatment of the suicidal patient. CME Syllabus and proceedings Summary, Am Psych Assoc Annual Mtg, 1987:33.

A-64. Schatzberg AF. Specificity and nonspecificity of antidepressants. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1987:33.

A-65. Schildkraut JJ, Schatzberg AF, Cole JO, Samson JA, Gerson B, Pappalardo KM. Catecholamine metabolism in depressive disorders. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1987:125.

A-66. Schatzberg AF. The use of the dexamethasone suppression test in psychiatric practice. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1987:160.

A-67. Schatzberg AF. HPA axis in anxiety disorders. Abstracts of the XVIII International Society of Psychoneuroendocrinology. Neuroendocrinology Letters. 1987; 9:147.

A-68. Rothschild AJ, Benes F, Woods B, Schatzberg AF. Brain C-T scan findings and HPA axis disruption in psychotic and nonpsychotic depressed patients. Abstracts of the XVIII International Society of Psychoneuroendocrinology. Neuroendocrinology Letters. 1987; 9:173.

A-69. Rothschild AJ, Benes F, Wood B, Bakanas E, Schatzberg AF. Relationships between brain C-T scan findings and cortisol in psychotic and nonpsychotic depressed patients. 26th Annual Mtg of the American College of Neuropsychopharmacology, 1987:186.

A-70. Dessain EC, Cole Jo, Schatzberg AF, Beake B, Bird M, Dugan S, Friedman L, Katz D, Marby D, Merzel A, O'Neil P, Salomon M, Schniebolk S. The impact of dosage schedule on adverse effects in a fluoxetine vs. doxepin double-blind study in pressed patients. 26th Annual Mtg of the American College of Neuropsychopharmacology, 1987:192.

A-71. Rothschild AJ, Benes FB, Woods B, Bakanas E, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Abstracts of the 78th Annual Mtg of the American Psychopathological Association, 1988.

- A-72. Samson JA, Rothschild AJ, Schildkraut JJ, Schatzberg AF. Learned helplessness and depressive disorders. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1988:120.
- A-73. Schatzberg AF, Rothschild AJ, Langlais PJ, Samson JA, Cole JO. Cortisol, dopamine, and psychosis in depression. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1988:120.
- A-74. Rothschild AJ, Benes FB, Woods B, Bakanas E, Schatzberg AF. Cortisol and brain CT relationships in depression. CME Syllabus and Proceedings Summary, Am Psych Assoc Annual Mtg, 1988:120-121.
- A-75. Dessain EC, Blatt CM, Schatzberg AF, Bird M, Cole JO. Differential cardiovascular effects of sertraline, fluoxetine, imipramine, amitriptyline, trimipramine and doxepin in depression. Abstracts of Panels and Posters. 27th Annual Mtg, American College of Neuropsychopharmacology. 1988:154.
- A-76. Samson JA, Rothschild AJ, Luciana M, Schildkraut JJ, Schatzberg AF. Correlates of helplessness in unipolar depressed patients. Abstracts of Panels and Posters, 27th Annual Mtg, American College of Neuropsychopharmacology. 1988:177.
- A-77. Schatzberg AF, Rothschild AJ, Samson JA, Langlais PJ, Schildkraut JJ. Glucocorticoids and dopamine in depressives and normal controls. Abstracts of Panels and Posters, 27th Annual Mtg, American College of Neuropsychopharmacology. 1988:84.
- A-78. Schatzberg AF, Dessain E, Mooney J, Cole JO, Schildkraut JJ. Triazolo-benzodiazepines in the treatment of depressed patients. Abstracts of British Association for Psychopharmacology Meeting - "Antidepressants - Thirty Years On", Galway, Ireland, 1988:S6-2.
- A-79. Nierenberg AA, Keck PE, Jr, Schatzberg AF, Rothschild AJ, Samson J. Catecholamine, cortisol, and psychosocial correlates of refractory depression. First International Conference on Refractory Depression. Philadelphia, October 6-7, 1988.
- A-80. Rothschild AJ, Samson JA, Schildkraut JJ, Cole JO, Schatzberg AF. Biologic and clinical characteristics of psychotic depression. Abstracts of Panels and Posters, 28th Annual Mtg, American College of Neuropsychopharmacology. 1989:204.
- A-81. Aaronson ST, Glod CA, Teicher MH, Schatzberg AF, Cole JO. Thioridazine in the treatment of borderlines. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:18.
- A-82. Schatzberg AF. Depression: Personality and biochemistry. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:21.
- A-83. Schatzberg AF. Differential diagnosis of panic. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:27.
- A-84. Schatzberg AF, Rothschild AJ, Samson JA, Meltzer HY, Langlais PJ, Cole JO. Overview of design, methods and results. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:173.

- A-85. Samson JA, Rothschild AJ, Schatzberg AF. Helplessness in depression: State or Trait? CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:173.
- A-86. Rothschild AJ, Samson JA, Schildkraut JJ, Cole JO, Schatzberg AF, Langlais PJ. Biochemical abnormalities in psychotic depression. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:173.
- A-87. Aaronson ST, Harper D, Schatzberg AF, Rothschild AJ. REM, sleep and chemical markers in depression. CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:174.
- A-88. Dessain EC, Schatzberg AF, Cole JO, Rothschild AJ, Mooney JJ, Schildkraut JJ. Can biochemical tests predict response to therapy? CME Syllabus and Scientific Proceedings in Summary Form, Am Psych Assoc Annual Mtg, 1989:174.
- A-89. Schatzberg AF. Differential dosing strategies by class and group. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1990:23.
- A-90. Schatzberg AF. The clinician's decision: Weighing benefit and risk. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1990:29.
- A-91. Schatzberg AF. Approaches to the patient with psychotic depression. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1990:29.
- A-92. Schatzberg AF. A treatment approach. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1990:37.
- A-93. Schatzberg AF, Rothschild AJ, Samson JA. Major depression with psychotic features. CME Syllabus & Proceeding Summary, Am Psych Assoc Annual Mtg, 1990:284.
- A-94. Samson JA, Rothschild AJ, Schildkraut JJ, Luciana M, Meltzer HY, Schatzberg AF. Correlates of plasma dexamethasone levels in depression. New Research Program and Abstracts, Am Psych Assoc Annual Mtg, 1990:NR180.
- A-95. Schatzberg AF, Samson JA, Rothschild AJ, Bruno R, Luciana M, Cole S. Early onset phobias and later major depression. New Research Program and Abstracts, Am Psych Assoc Annual Mtg, 1990:NR296.
- A-96. Rothschild AJ, Schatzberg AF, Samson JA, Schildkraut JJ, Luciana M, Letson M. Cortisol and outcome in depression. New Research Program and Abstracts, Am Psych Assoc Annual Mtg, 1990:NR409.
- A-97. Schatzberg AF, Rothschild AJ, Samson JA, Bond TC. Glucocorticoid/dopamine interactions in normal controls and depressed patients. Abstracts of Presentations, Twenty-First Congress, International Society of Psychoneuroendocrinology, 1990:30.

- A-98. Rothschild AJ, Schatzberg AF, Samson JA. HPA axis activity and social adjustment in depression. Abstracts of Presentations, Twenty-First Congress, International Society of Psychoneuroendocrinology, 1990:168.
- A-99. Schatzberg AF. Drug therapy and depression. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1991:17.
- A-100. Schatzberg AF. Recent developments in antidepressant drug treatment. CME Syllabus & Proceedings Summary, Am Psych Assoc Annual Mtg, 1991:25.
- A-101. Posener JA, Schatzberg AF, Schildkraut JJ. Adrenocorticotrophic and ovine corticotropin releasing hormone effects on dopamine activity in man. New Research Program and Abstracts, Am Psych Assoc Annual Mtg, 1991:NR479.
- A-102. Green AI, Alam MY, Pappalardo KM, Salzman C, Schatzberg AF, Schildkraut JJ. Catecholamine metabolites and clozapine response. New Research Program and Abstracts, Am Psych Assoc Annual Mtg, 1991:NR404.
- A-103. Schatzberg AF, Posener JA, Rothschild AJ. The effects of oCRF and ACTH on dopamine systems in man. Abstracts of the 5th World Congress of Biological Psychiatry, Supplement to Biological Psychiatry, 1991; 29(11S):48S.
- A-104. Schatzberg AF, Posener JA. Triazolobenzodiazepines in the treatment of depression: Fact or fiction. Abstracts of the 5th World Congress of Biological Psychiatry, Supplement to Biological Psychiatry, 1991; 29(11S):133S.
- A-105. Green AI, Alam MY, Salzman C, Schatzberg AF, Schildkraut JJ. Plasma HVA and response to clozapine. Abstracts of the 5th World Congress of Biological Psychiatry, Supplement to Biological Psychiatry, 1991; 29(11S):410S.
- A-106. Schatzberg AF, Samson JA, Rothschild AJ, Bruno R: Childhood - onset social phobia and adult major depression. Abstracts of Panels and Posters, 30th Annual Mtg American College of Neuropsychopharmacology, December, 1991:38.
- A-107. Salzman C, Schatzberg AF, Miyawaki E, Albanese M, Wolfson A, Looper J: Fluoxetine in BPD. 1992 New Research Program and Abstracts, 145th Annual Mtg of the Am Psych Assoc, 1992:NR 524.
- A-108. Schatzberg, AF, Bowden CL, Rosenbaum AH, Schildkraut JJ: Prediction of response to fluoxetine versus desipramine, CME Syllabus and Proceedings Summary, 145th Annual Mtg of the Am Psych Assoc, 1992; 25D:44.
- A-109. Schatzberg AF, Bowden CL, Rosenbaum AH, Samson JA, Dessain E, Schildkraut JJ: Effects of fluoxetine and desipramine on urinary catecholamine and metabolite excretion in major depression. Proceedings of the 18th Collegium International Neuro-Psychopharmacologicum Congress, Nice, France; Clinical Neuropharmacology, 1992; 15(S1, Part B): 415B.
- A-110. Rosenbaum AH, Schatzberg AF, Bowden CL, Samson JA, Schildkraut JJ: MHPG as a predictor of clinical response to fluoxetine. Proceedings of the 18th

Collegium International Neuro-Psychopharmacologicum Congress, Nice, France; Clinical Neuropharmacology, 1992; 15(S1, Part B): 209B.

A-111. Bowden C, Schatzberg A, Rosenbaum A, Contreras S, Schildkraut J, Dessain E: Effects of fluoxetine and desipramine on platelet imipramine binding in major depression. Proceedings of the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress, Nice, France, Clin Neuropharmacology 1992; 15(S1, Part B): 329B.

A-112. Schatzberg AF, Posener J, Rothschild AJ, Samson JA. HPA axis effects on dopamine activity and cognition: Implications for delusional depression. Proceedings of the XXIII Congress of the International Society of Psychoneuroendocrinology, Madison, WI, 1992:57.

A-113. Bowden CL, Schatzberg AF, Rosenbaum AH, Javors MA, Contreras S, Samson JA, Schildkraut JJ. Relationships of imipramine binding to clinical response during treatment with serotonin uptake inhibitors vs. desipramine. ACNP 31st Annual Mtg, 1992:66.

A-114. Mooney JJ, Samson JA, Alpert J, Cole JO, Schatzberg AF, Schildkraut JJ. Correlations between receptor-mediated and nonreceptor-mediated measures of platelet adenylate cyclase (AC) activity in depressed patients. ACNP 31st Annual Mtg, 1992:67.

A-115. Salzman C, Wolfson AN, Miyawaki E, Schatzberg AF, Looper J, Henke R, Albanese M, Schwartz, J. Fluoxetine treatment of anger in borderline personality disorder. ACNP 31st Annual Mtg, 1992:24.

A-116. Schatzberg AF. Issues in selection of specific antidepressants. 1993 CME Syllabus and Proceedings Summary, Am Psych Assoc 146th Annual Mtg, 1993:19.

A-117. Schatzberg AF. Pharmacotherapy of the suicidal patient. 1993 CME Syllabus and Proceedings Summary, Am Psych Assoc 146th Annual Mtg, 1993:26.

A-118. Schatzberg AF. Early interventions in anxiety: Why and when?. 1993 CME Syllabus and Proceedings Summary, Am Psych Assoc 146th Annual Mtg, 1993:38.

A-119. Schatzberg AF. Posener JA, Rothschild AJ, Schildkraut JJ. HPA axis effects on dopamine systems in man. 1993 CME Syllabus and Proceedings Summary, Am Psych Assoc 146th Annual Mtg, 1993:123.

A-120. Rothschild AJ, Schatzberg AF, Samson JA, Besette M, Carter-Campbell J. HPA axis activity and outcome in depression. 1993 CME Syllabus and Proceedings Summary, Am Psych Assoc 146th Annual Mtg, 1993:222.

A-121. Rothschild AJ, Schatzberg AF. Neurobiologic differences between psychotic and nonpsychotic depressed patients. Abstracts of Panels and Posters, American College of Neuropsychopharmacology Annual Mtg, 1993:18.

A-122. Schatzberg AF. Glucocorticoid/monoamine interactions: Implications for delusional depression. Plenary Lectures and Symposia Abstracts, American College of Neuropsychopharmacology Annual Mtg, 1994; (Suppl 1):932.

A-123. Koran L, Delgado P, Schatzberg AF, Russell J, Klein DN. Comorbidity and course of illness in chronic depressions. Oral Communications and Poster Abstracts, American College of Neuropsychopharmacology Annual Mtg, 1994; (Suppl 2):234.

A-124. Posener JA, Schildkraut JJ, Williams GH, Salomon MS, McHale NL, Schatzberg AF. Delayed effects of CRH and ACTH on dopamine in man. Am Psych Assoc, 1994:NR7.

A-125. Posener JA, Schatzberg AF, Schildkraut JJ. HPA Axis effects on dopamine activity in man. Am Psych Assoc, 1994:NR 423.

A-126. Schatzberg AF, Posener JA, Lyons DC, Levine S. CRF and dopamine interactions. Summer Neuropeptide Conference, Martha's Vineyard, MA, 1995.

A-127. Kornstein SG, Yonkers KA, Schatzberg AF, Manber R, Belyea-Caldwell S. Premenstrual exacerbation of depression. NCDEU 35th Annual Mtg, 1995:12.

A-128. Lindley SE, Schatzberg AF, Wong DL. Acute and chronic effects of elevations in peripheral corticosterone on central dopaminergic neuronal activity. American College of Neuropharmacologic Abstracts, 1995.

A-129. Patel JK, Green AI, Banov MD, Tchen M, Schatzberg AF, Cole JO. Clozapine use in treatment refractory mania and psychosis. Am Psych Assoc 148th Annual Mtg, 1995:183.

A-130. Thase ME, Keller MB, Gelenberg AJ, Hirschfeld RMA, Schatzberg AF. Double-blind crossover antidepressant study: Sertraline vs. imipramine. Am Psych Assoc 148th Annual Mtg, 1995:101.

A-131. Thase ME, Keller MB, Gelenberg A, Hirschfeld R, Schatzberg AF. Double-blind crossover antidepressant study: sertraline vs. imipramine. NCDEU 35th Annual Mtg, 1995.

A-132. Flynn LM, Schatzberg AF, Luchins DJ, Dincin J. "Mental Illness 101": A primer for families. Am Psych Assoc 48th Institute on Psychiatric Services, 1996:24.

A-133. Kornstein SG, Schatzberg AF, Manber R, Burke LP. Premenstrual exacerbation of depression. Am Psych Assoc Annual Mtg, 1996:58.

A-134. Kornstein SG, Schatzberg AF, Yonkers KA, Thase ME, Keitner GI. Gender differences in chronic depression. Am Psych Assoc Annual Mtg, 1996:303.

A-135. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. Effects of alterations in peripheral corticosterone on mesocortical and tuberoinfundibular dopaminergic neurochemical indices. Soc Neurosc Abstracts, 1996.

- A-136. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. Effects of corticosterone on central catecholaminergic neurochemical indices in Fisher 344 rats. 8th Inter Catechol Symposium, 1996.
- A-137. Lindley SE, Wong DL, Schatzberg AF. Chronic corticosterone on mesocortical dopamine utilization. Soc Biol Psychiatry, 1996.
- A-138. Lyons D, Wang O, Lindley S, Schatzberg AF. Corticosteroid-dopaminergic interactions in monkeys treated with metyrapone. Society for Neuroscience Abstracts, 1996:22, 496.
- A-139. Posener JA, Rothschild AF, Schildkraut JJ, Schatzberg AF. HPA axis affects on dopamine activity in man. Am Psych Assoc Annual Mtg, 1996:65.
- A-140. Rosebaum AH, Ginsburg K, Rosenberg R, Davis J, Schatzberg AF. Treatment of major depressive disorder (MDD) and manic depressive illness with gonadotropin-releasing hormone agonist therapy (GnRHa). ISPNE XXVIIth Congress, 1996:101.
- A-141. Schatzberg AF, Bowden CL, Rosenbaum AH. Severity, catecholamines and treatment response. Am Psych Assoc Annual Mtg, 1996:296.
- A-142. Schatzberg AF, DeBattista C. Agitation in depression: Assessment and treatment. Am Psych Assoc 48th Institute on Psychiatric Services, 1996:39.
- A-143. Schatzberg AF, Koran L, DeBattista C, Gelenberg A, Hirschfeld R, Keitner G, Keller MB, Klein D, Kocsis JH, Kornstein S, Thase M. Sertraline or imipramine for chronic depression: 7-month results. NCDEU, 1996.
- A-144. Schatzberg AF, Kornstein SG, Thase ME, Keitner GI. Gender-based assessment of outcome. Annual Mtg, 1996:169.
- A-145. Schatzberg AF, Posener J, Lindley S, Lyons D, Wong D. HPA Axis/Dopamine interactions. ISPNE XXVIIth Congress, 1996:37.
- A-146. Schatzberg AF. Recent advances in refractory mood disorders. 48th Institute on Psychiatric Services, 1996:70.
- A-147. Keller MB, Kocsis JH, McCullough JP, Trapp GA, Schatzberg AF, Thase ME. Sertraline maintenance therapy in chronic depression. Am Psych Assoc Annual Mtg, 1997:181.
- A-148. Posener JA, Schatzberg AF, Rothschild AJ. Glucocorticoid feedback effects on ACTH secretion in depression. International Society for Psychoneuroendocrinology, 1997:47.
- A-149. Schatzberg AF, Posener JA, Lindley S, Belanoff J, DeBattista C. HPA axis interventions as treatment of depression. International Society for Psychoneuroendocrinology, 1997.

A-150.Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. Strain differences in mesotelencephalic dopaminergic neuronal regulation in Fischer 344 and Lewis rats, Soc Neurosci Abstracts, 1997.

A-151.Lindley SE, Bengoechea TG, Wong DL, Schatzberg AF. Corticosterone effects on clozapine and gamma-butyrolactone induced changes in dopamine utilization, ISPNE, 1997.

A-152.Lyons DM, Martel FL, Levine S, Risch NJ, Schatzberg AF. Psychosocial stress: Postnatal and genetic sources of vulnerability and resilience. Society for Neuroscience Abstracts, 1997:23, 1079.

A-153.Lyons DM, Martel FL, Levine S, Risch NJ, Schatzberg AF. Individual differences in pituitary-adrenocortical physiology. Psychoneuroendocrinology, 1997:22, S196.

A-154.Patel PD, Lyons DM, Zhang Z, Ngo H, Schatzberg AF. Corticosteroid receptors in a new world primate, *Saimiri sciureus*. Psychoneuroendocrinology, 1997:22, S197.

A-155.Patel PD, Lyons DM, Zhang Z, Ngo H, Schatzberg AF. Molecular cloning and functional characterization the glucocorticoid receptor from the new world primate, *Saimiri sciureus*. Society for Neuroscience Abstracts, 1997:23, 1240.

A-156.Schatzberg AF, Kumar A, Alexopolous GS, Arnold SE, Krishnan KRR, Robinson R, Yesavage J. Is there a distinct "Vascular depression" in late-life? ACNP 36th Annual Mtg, 1997:2.

A-157.Schatzberg AF. Management of chronic and recurrent depression. Am Psych Assoc Annual Mtg, 1997:285.

A-158.Thase ME, Keller MB, Gelenberg A, Hirschfeld R, Schatzberg AF. Double-blind crossover antidepressant study: Sertraline vs. imipramine. 6th World Congress of Biological Society Mtg, 1997:230S.

A-159.Kocsis JH, Schatzberg AF, Rush AJ, Kornstein S, Klein D., Hirschfeld RM. Maintenance therapy of chronic depression: A placebo-controlled trial of sertraline. 6th World Congress of Biological Society Mtg, 1997:240S.

A-160.Schatzberg AF. Where do you turn when SSRI's fail? Am Psych Assoc Annual Mtg, 1997:272.

A-161.DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of SSRIs in treatment resistant depression. NCDEU Boca Raton, 1998.

A-162.Schatzberg AF, Posener JA, DeBattista C, Kalehzan M, Lyons DM, Williams GH. HPA axis in psychotic major depression. International Society for Psychoneuroendocrinology, 1998.

A-163.Haraldsen I, Kalehzan M, van Maasdam J, Schatzberg AF, Finseth A. Effect of long-term sex hormone substitution on cognitive brain function. XXIXth ISPNE Congress, 1998:13.

- A-164. Schatzberg AF, Posener J, DeBattista, C, Kalehzan M, Lyons D, Williams G. HPA axis in psychotic major depression. XXIXth ISPNE Congress. 1998:25.
- A-165. Kocsis JH, Dunner D, Fawcett J, Hirschfeld R, Nemeroff C, Keller M, McCullough JP, Rush AJ, Schatzberg AF, Thase M, Borian F, Jody D. Nefazodone HCl, CBT-CD and combination therapy for the acute treatment of chronic depression. ACNP 37th Annual Mtg, 1998:205.
- A-166. Kocsis JH, Keller M, Schatzberg AF, Thase M, McCullough J, and the Chronic Depression Treatment Study Group. Is combined therapy the treatment of choice for chronic depression? ACNP 37th Annual Mtg, 1998:316.
- A-167. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. Strain differences in mesotelencephalic dopaminergic responses to glucocorticoids, Soc Neurosci Abstracts, 1998.
- A-168. Lyons DM, Lopez J, Lindley SE, Schatzberg AF. Corticosteroids, catecholamines, and cognitive control on an object retrieval task. Society for Neuroscience Abstracts, 1998:24, 1380.
- A-169. Keller MB, McCullough JP, Rush AJ, Klein D, Schatzberg AF, Gelenberg AJ, Thase ME. Nefazodone HCl, cognitive behavioral analysis system of psychotherapy and combination therapy for the acute treatment of chronic depression. Am Psych Assoc Annual Mtg, 1999:NR405.
- A-170. Schatzberg AF. Clinical efficacy of reboxetine in major depression. Am Psych Assoc Annual Mtg, 1999:40D.
- A-171. Pardes H, Ruiz P, Gorman JM, Grant I, Halmi KA, Schatzberg AF. Research advances in psychiatry: An update for the clinician. Am Psych Assoc Annual Mtg, 1999:297.
- A-172. Schatzberg AF, DeBattista C, Kalehzan M, Posener J. HPA axis activity and cognition in major depression. ISPNE Congress Annual Mtg, 1999:34.
- A-173. Schatzberg AF, DeBattista C, Posener J, Rothschild AJ. Biological characteristics of chronic major depression. ACNP 38th Annual Mtg, 1999:1.
- A-174. Charney D, Shore D, Bowden C, McDougle C, Hirschfeld R, Kraemer H, Gorman J, Schatzberg AF, Kane J, Ross J, Lieber C, Hall L, Lewis L. The use of placebo in clinical trials: what changes are necessary? ACNP 38th Annual Mtg, 1999:15.
- A-175. Schatzberg AF, DeBattista C, Posener J. HPA axis activity and cognition in depression. ACNP 38th Annual Mtg, 1999:56.
- A-176. Lindley SE, Wan D, Gengoechea TG, Wong DL, Schatzberg AF. Effects of chronic stress and glucocorticoid antagonism of mesocortical dopaminergic utilization. ACNP 38th Annual Mtg, 1999:198 (Poster Session II).

A-177. Schatzberg AF, Cantillon M. Antidepressant early response and remission of venlafaxine (Effexor) and fluoxetine (Prozac) in geriatric outpatients. 22nd CINP Congress. 2000:S191.

A-178. Haraldsen IR, Opjordsmoen S, Schatzberg AF, Finset A. Is the neuropsychological pattern of transsexual patients different from heterosexuals? 2nd Int Congress on Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece. 2000:S120.

A-179. Belanoff J, Schatzberg AF. Glucocorticoid antagonists. 2nd Int Congress on Hormones, Brain, and Neuropsychopharmacology, Rhodes, Greece. 2000:S56.

A-180. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Ficek SF. CRF, the HPA axis and psychotic depression. 2nd Int Congress on Hormones, Brain, and Neuropsychopharmacology, Rhodes, Greece. 2000:S6.

A-181. Schatzberg AF, DeBattista C, Posener J. Glucocorticoids & cognition in depression. 13th Congress of ECNP. 2000:S180.

A-182. Schatzberg AF, Cantillon M. Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients. 13th Congress of ECNP. 2000:S225.

A-183. Kupfer DJ, Hyman SE, Greden JF, Schatzberg AF, Pincus HA, Reynolds III CF. Recruiting and retaining future generations of clinical and intervention researchers in mental health. ACNP 39th Annual Meeting, San Juan, Puerto Rico. 2000:15.

A-184. Schatzberg AF, Kremer C, Rodrigues HE, The Mirtazapine vs. Paroxetine Study Group. Mirtazapine versus paroxetine in elderly depressed patients. ACNP 39th Annual Meeting, San Juan, Puerto Rico, 2000:97.

A-185. Rush AJ, Thase ME, Menber R, Kornstein SG, Schatzberg AF, Trivedi MH, Borian FE. Effects of nefazodone, CBAS psychotherapy (CBAS) and their combination on sleep disturbance in chronic major depression. ACNP 39th Annual Meeting, San Juan, Puerto Rico, 2000:146.

A-186. Hirschfeld RMA, Dunner DL, Keitner G, Klein D, Koran LM, Kornstein SG, Markowitz J, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Keller MB. Psychosocial functioning in chronic major depression: Treatment with nefazodone, CBASP, and their combination. ACNP 39th Annual Meeting, San Juan, Puerto Rico, 2000:147.

A-187. DeBattista C, Solvason HB, Flores BJ, Schatzberg AF. Modafinil as an adjunctive agent in the treatment of fatigue and hypersomnia associated with depression. ACNP 39th Annual Meeting, San Juan, Puerto Rico. 2000:175.

A-188. Murphy GM, Schatzberg AF. Pharmacogenetics of mirtazapine and paroxetine in the treatment of geriatric major depression. ACNP 39th Annual Meeting, San Juan, Puerto Rico. 2000:235.

- A-189. Schatzberg AF. Mirtazapine vs. paroxetine in elderly depressed patients. APA Annual Meeting, New Orleans, LA. 2001:130.
- A-190. DeBattista C, Solvason HB, Schatzberg AF, Kendrick E. A placebo-controlled, double-blind study of bupropion sustained release for sexual dysfunction. APA Annual Meeting, New Orleans, LA. 2001:144.
- A-191. DeBattista C, Solvason HB, Kendrick E, Schatzberg AF. Modafinil as adjunctive in treatment of fatigue and hypersomnia in major depression. APA Annual Meeting, New Orleans, LA. 2001:144.
- A-192. Schatzberg, AF. Benefits of different classes of antidepressants for geriatric depression. APA Annual Meeting, New Orleans, LA. 2001: Proceedings: 285.
- A-193. Schatzberg AF, Kremer C, Rodrigues H, DeBattista C, Murphy G. Mirtazapine vs. Paroxetine in elderly depressed patients. 41st Annual NCDEU Meeting, Phoenix, AR. 2001: I-62.
- A-194. Schatzberg AF, Posener J, DeBattista C, Belanoff J. HPA Axis activity in the etiology and treatment of psychotic depression. 7th World Congress of Biological Psychiatry Meeting, Berlin, Germany. 2001:S39:2.
- A-195. Schatzberg AF, Ohayon M. Recent Studies on the Epidemiology and biology of psychotic depression. Abstracts ACNP 40th Annual Meeting. 2001:57.
- A-196. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Schatzberg AF. Rapid reversal of psychotic major depression using C-1073 (Mifepristone). Abstracts of the ACNP 40th Annual Meeting. 2001:58.
- A-197. Schatzberg AF, Belanoff J, DeBattista C. Delusional major depression: new treatment approaches. Abstracts of the ECNP Meeting. 2001:196.
- A-198. Lindley SE, Her S, Cao Y, Selwood S, Schatzberg AF, Murphy GM, Lyons DM. Glucocorticoid Regulation of Gene Expression in the Medial Prefrontal Cortex and Striatum. Abstracts, Soc Neurosci, 2002.
- A-199. Schatzberg AF. Can genetic differences predict the response to medication? Abstracts, Volume 5 (1), Collegium Internationale Neuropsychopharmacologicum, 23rd CINP Congress. 2002:S224.
- A-200. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu E-E, Schold SC, Schatzberg AF. Rapid reversal of psychotic major expression using C-1073. Abstracts of the NCDEU, 2002.
- A-201. Lyons DM, Moseley ME, Schatzberg AF. Stress, Connectivity, and Cognitive Decline. Abstracts of the ACNP 42nd Annual Meeting. 2003:12.
- A-202. Schatzberg AF. Antigluocorticoid treatments for depression with glucocorticoid receptor antagonists, CRF antagonists: rationale and implications. Abstracts of the 34th Annual ISPNE Meeting, 2003.

A-203. Wilkinson C, Hammett JM, Peskind ER, Raskind MA, Belanoff JK, Schatzberg AF, Lupien SJ: Mediation of human glucocorticoid feedback inhibition by both mineralocorticoid and glucocorticoid receptors at the circadian peak. Abstracts 6th IBRO World Congress Neuroscience. 2003:318.

A-204. Schatzberg AF. Glucocorticoid antagonists in psychotic major depression. Abstracts of the 16th ECNP Congress Meeting, 2003.

A-205. Schatzberg AF, Flores B, Belanoff J, Solvason B, Keller J, Gomez R. HPA axis activity, psychosis and cognition in major depression. Abstracts, ISAD Meeting, 2004.

A-206. Schatzberg AF, DeBattista C, Flores B, Posener J. Modulators of the HPA axis. Presentation ISAD Conference Mtg, 2004.

A-207. Schatzberg AF. Antigluccorticoids and depression. Poster - Abstracts of the Society of Biological Psychiatry 59th Annual Scientific Convention & Program, 2004.

A-208. Schatzberg AF, Flores B, Keller J, Lindley SE, Solvason, B. Glucocorticoid Antagonists in Depression. New Research Abstracts, American Psychiatric Association, 2004.

A-209. Keller J, Gomez RG, Gumina, HK, Schatzberg, AF. Cortisol, psychiatric symptoms, and cognition in psychotic and nonpsychotic depression. Annual Meeting, American Psychological Association, 2004.

A-210. Gomez R, Keller J, Fleming S, Schatzberg AF. The Neuropsychological Profile of Psychotic Major Depression (PMD). Annual Meeting, American Psychological Association, 2004.

A-211. Schatzberg AF. Recent Studies in Psychotic Major Depression. Annual Meeting, XXIVth Congress of the CINP, 2004.

A-212. Schatzberg AF, Flores B, Solvason B. An update on glucocorticoid antagonists in depression. Abstracts, World Federation of Societies of Biological Psychiatry, International Congress of Biological Psychiatry, 2004. World Journal of Biol Psychiatry (2004) 5 (Suppl.1), p. 18.

A-213. Keller M, Kocsis J, Kornstein, Rothschild A, Shelton R, Trivedi M, Ninan P, Gelenberg A, Dunner D, Hirschfeld R, Schatzberg A, Thase M, Benattia I, Del Greco F. Abstracts, Annual Meeting, ACNP 2004. Neuropsychopharmacology (2004) 29 (Suppl. 1), p. S148.

A-214. Schatzberg AF, Flores B, Keller J, Solvason B. Antidepressant interventions on the HPA system: use of glucocorticoid antagonists. Abstracts of the World Psychiatric Association, 2004. World Psychiatry 3 (Supp 1): 56, 2004.

A-215. Schatzberg AF. Finding a solution: innovative and balanced treatments for achieving remission. Abstracts of the World Psychiatric Association, 2004. World Psychiatry 3 (Supp 1): 350, 2004.

- A-216. Lindley SE, Kenna HA, Flores BH, Solvason HB, Schatzberg AF. Decrease in fasting plasma insulin concentrating with mifepristone therapy. Abstracts of the 36th Annual ISPNE Meeting, 2005.
- A-217. Wilkinson CW, Peskind ER, Lash BC, Eliza S, Rieskse RG, Raskind MA, Belanoff JK, Schatzberg AF, Lupien SJ. Aging-related deficits in glucocorticoid feedback inhibition reflect altered mineralocorticoid receptor function. Abstracts of the 36th Annual ISPNE Meeting, 2005.
- A-218. Schatzberg AF. Antipsychotic and antidepressant use in personality traits treatment. Annual Meeting, American Psychiatric Association, 2005.
- A-219. Schatzberg AF, Hales DJ, Rapaport MH. Focus life: Major depressive disorder. Annual Meeting, American Psychiatric Association, 2005.
- A-220. Lyons ML, Parker KJ, Katz M, Buckmaster CL, Schatzberg AF. Neural substrates of stress inoculation determined in vivo by brain imaging in monkeys. ACNP 44th Annual Meeting, Waikoloa, Hawaii. 2005:S59.
- A-221. Beebe KL, Block T, DeBattista C, Blasey C, Schatzberg AF. Mifepristone for the prevention of olanzapine-induced weight gain in rats. ACNP 44th Annual Meeting, Waikoloa, Hawaii. 2005:S130.
- A-222. Kocsis JH, Keller MB, Klein DN, Ninan PT, Schatzberg AF, Thase ME, Trivedi MH, Wisniewski S, Gelenberg AJ. The revamp medication algorithm for chronic depression: preliminary results. ACNP 44th Annual Meeting, Waikoloa, Hawaii. 2005:S176.
- A-223. Lyons DM, Karssen AM, Li JZ, Her S, Patel PD, Bunney WE, Jones EG, Watson SJ, Akil H, Meyers RM, Schatzberg AF. Social stress-induced changes in expression profiles in primate prefrontal cortex. Abstracts of the Society of Biological Psychiatry 61st Annual Scientific Convention & Program, 2006:194S.
- A-224. Schatzberg AF. Using pharmacogenetics in practice. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2006:26.
- A-225. Schatzberg AF. Chronic pain and major depression. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2006:59.
- A-226. Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF. Addition of atomoxetine for depression in completely responsive to sertraline: a randomized, double-blind, placebo-controlled study. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2006:74.
- A-227. Buckley T, Schatzberg AF. The effects of a Glucocorticoid Receptor (GR) Antagonist on the body clock – a pilot study. ACNP 45th Annual Meeting, Hollywood, Florida. 2006:S234.

- A-228. Schatzberg AF. Mediator-moderator analysis to predict onset of hyperglycemia with atypical neuroleptics. Abstracts of the NCDEU, 2006.
- A-229. Schatzberg AF. Chronic depression: medication (Nefazodone) or psychotherapy (CBASP) is effective when the other is not. Abstracts of the NCDEU, 2006.
- A-230. Schatzberg AF. Augmentation and combination strategies in treatment resistant depression. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2007:8.
- A-231. Schatzberg AF. Agomelatine, a novel antidepressant, is effective in major depressive disorder across gender and severity of depression. New Research Abstracts, Annual Meeting, American Psychiatric Association, 2007:163.
- A-232. Schatzberg AF, Keller J, Buckley T, Gomez R, Reiss AI, Grecius M. Structural and functional MRI in psychotic and nonpsychotic depression. Abstracts of the 36th Annual ISPNE Meeting, 2007.
- A-233. Lyons DM, Patel PD, Lee AG, Katz M, Schatzberg AF. Corticosteroid receptor expression in primate hippocampus and prefrontal cortex. Abstracts of the 36th Annual ISPNE Meeting, 2007.
- A-234. Lyons DM, Katz M, Parker KJ, Buckmaster CL, Bammer R, Liu C, Ottet C, Schaer M, Eliez S, Schatzberg AF. Stress-induced neuroadaptations in primate prefrontal development. Abstracts of the 36th Annual ISPNE Meeting, 2007.
- A-235. Schatzberg AF, Friedman AS, Rothschild AJ, Trivedi MH, Dunner DL, Gelenberg AJ, Ninan P, Shelton RC, Zajecka JM, Ahmed S, Musgnung J, Pederson R. Prevalence of pain and impact on treatment outcomes in patients with recurrent major depressive disorder. Abstracts of the 46th Annual ACNP Meeting, Boca Raton, Florida. 2007:68.
- A-236. Kerman IA, Bernard R, Thompson RC, Burke S, Meng F, Evans SJ, Jones EG, Bunney WE, et al. Evidence for transcriptional dysregulation in the dorsal raphe in major depressive disorder. Abstracts of the 46th Annual ACNP Meeting, Boca Raton, Florida. 2007:186.
- A-237. Rasgon N, Kenna H, Williams KE, Powers B, Schatzberg AF. Adjunctive rosiglitazone treatment in MDD patients with insulin resistance. Abstracts of the 46th Annual ACNP Meeting, Boca Raton, Florida. 2007:238.
- A-238. Dunn LO, Kupfer DJ, Schatzberg AF, Grochocinski VJ, Pilkonis PA, DeRosier ME, O'Hara RM. Growing the next generation of psychiatric researchers: The Career Development Institute for Psychiatry. Abstracts of the 46th Annual ACNP Meeting, Boca Raton, Florida. 2007:308.
- A-239. Amit E, Anguiano JM, Keller KE, Menon V, Schatzberg AF. Alterations in frontolimbic systems for emotion regulation in major depression and generalized anxiety. Abstracts of the Society of Biological Psychiatry 61st Annual Scientific Convention & Program, Washington, DC. 2008:58S.

A-240. Schatzberg AF. Addressing unmet needs in psychotic depression. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2008:8.

A-241. Schatzberg AF. Brief medication visits: when and how? Presidential Symposium, Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2008:327.

A-242. Schatzberg AF, Keller J, Lyons D, Reiss A. Recent MRI studies in depression: Relationship to HPA axis activity. Annual Meeting, XXVI Congress of the CINP, 2008:S-12.05.

A-243. Burmeister M, Scott LJ, Li JZ, Absher D, Thompson RC, Meng F, Southwick A, Barchas JD, Bunney W, Jones EG, Schatzberg, AF, et al. Genomic and expression studies in bipolar disorder: Clues for new drug targets. Annual Meeting, XXVI Congress of the CINP, 2008:S-19.01.

A-244. Schatzberg AF, Belanoff J. Glucocorticoid receptor antagonists as a novel treatment option in psychotic depression. Annual Meeting, XXVI Congress of the CINP, 2008:S-20.03.

A-245. Kalali A, Evans K, Vaccarino A, Sills T, Kennedy S, Kobak K, Ferguson J, Wunderlich G, Sheehan D, Williams J, Schatzberg AF. The depression inventory development workgroup: Results from the second validation study. Annual Meeting, XXVI Congress of the CINP, 2008:P-104.129.

A-246. Lyons DM, Katz M, Schaer M, Parker KJ, Ottet M-C, Buckmaster CL, Eliez S, Schatzberg AF. Prefrontal myelination, cortical expansion, and stress-induced emotional resilience. Abstracts of the 39th Annual ISPNE Meeting, 2008.

A-247. Schatzberg AF. Recent HPA axis studies in anxiety and depression. Abstracts of the 39th Annual ISPNE Meeting, 2008.

A-248. Schatzberg AF, Keller J, Lyons D. Hippocampal and amygdale volumes in depressive subtypes. Abstracts of the 39th Annual ISPNE Meeting, 2008.

A-249. Kalali A, Vaccarino A, Evans K, Kennedy S, Kobak K, Sills T, Sheehan D, Williams J, Greist J, Schatzberg A. The depression inventory development workgroup: results from the second validation study. Proceedings of the ECNP satellite symposium. *European Neuropsychopharm.* 2008; 18(S4):S298.

A-250. Schatzberg AF, Otte C, Young A, Belanoff J. HPA axis interventions in psychiatry. Abstracts of the 40th Annual ISPNE Meeting, 2009.

A-251. Miller A, Schatzberg AF. The great debate in memoriam of Gig Levine. Abstracts of the 40th Annual ISPNE Meeting, 2009.

A-252. Schatzberg AF. Recent and anticipated advances in the treatment of depression: implications for the profession. 61st Institute on Psychiatric Services, 2009:35.

- A-253. Schatzberg AF, Keller J, Sudheimer J, Greicius M. Connectivity of the subgenual cortex and HPA axis in depression. Abstracts of the Society of Biological Psychiatry 65th Annual Scientific Convention & Program, 2010:3S.
- A-254. Sequeira A, Morgan L, Cartagena P, Walsh D, Choudary P, Jones EG, Schatzberg AF, Watson SJ, Li J, Akil H, Myers R, Bunney WE, Vawter MP. Metabolism gene expression and genetic variants: implications for mood disorders and suicide. Abstracts of the Society of Biological Psychiatry 65th Annual Scientific Convention & Program, 2010:134S.
- A-255. Schatzberg AF. Connectivity of the subgenual cortex and HPA axis in depression. Syllabus and Proceedings Book, 163rd Annual Meeting, American Psychiatric Association, 2010:PS1-1, p.1.
- A-256. Schatzberg AF, Deisseroth K. Presidential Symposium 2: Can basic and translational neuroscience improve treatment in psychiatry? Syllabus and Proceedings Book, 163rd Annual Meeting, American Psychiatric Association, 2010:PS3-1, p.5.
- A-257. Schatzberg, AF, Snyder SH. Presidential Symposium 3: Recent advances in psychiatric genetics: from fundamental discovery to clinical implication. Syllabus and Proceedings Book, 163rd Annual Meeting, American Psychiatric Association, 2010:PS4-1, p.7.
- A-258. Schatzberg, AF, Glick ID, DeBattista C. Master Course 02: Staying on the cutting edge of advances in clinical psychopharmacology. Syllabus and Proceedings Book, 163rd Annual Meeting, American Psychiatric Association, 2010: p.12.
- A-259. Janicak PG, Ziad Nahas, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, Marangell LB, Rosenquist P, McCall WV, Kimball J, O'Reardon JP, Loo C, Husain MH, Krystal A, Gilmer W, Dowd SM, Demitrack MA, Schatzberg AF. Long-term durability of acute response to transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression. Syllabus and Proceedings Summary, Annual Meeting, American Psychiatric Association, 2010:236.
- A-260. Etkin A, Schatzberg A. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in anxiety versus depression. Abstracts of the ACNP 49th Annual Meeting, 2010:S265.
- A-261. Sudheimer K, Etkin A, Greicius M, Keller J, Schatzberg A. Disturbances in resting state functional connectivity of amygdala subregions in patients with psychotic and nonpsychotic major depression. Abstracts of the ACNP 49th Annual Meeting, 2010:S367.
- A-262. Binder E, Nemeroff C, Schatzberg, A, Schlaepfer T, Kees B, Haazen L, De Chaffoy D, Buntinx E. Interaction of pampamperone augmentation of citalopram and genetic variables in the prediction of antidepressant response. Abstracts of the ACNP 49th Annual Meeting, 2010:S383.

A-263. Williams LM, Rush AJ, Koslow S, Wisniewski S, Cooper N, Nemeroff C, Schatzberg AF, Gordon E. Identifying gene, brain, cognition and emotion markers for response to antidepressants: the iSPOT-D trial. Abstracts of the Society of Biological Psychiatry 66th Annual Scientific Convention Program, 2011:135S.

A-264. Schatzberg AF. Stress, cortisol and psychosis in depression. Syllabus Book, 164th Annual Meeting, American Psychiatric Association, 2011:Lecture 18, p.42.

A-265. Peselow ED, Glick I, Schatzberg AF. The importance of biological psychiatry and clinical psychopharmacology in teaching psychiatric residents. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2011:S12-1, p.168.

A-266. Schatzberg, AF. Personalized medicine: psychotic major depression. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2011:S87-2, p.338.

A-267. Schatzberg AF, DeBattista C, Rason NL, Glick ID, Chang K, Ketter TA. Essential Psychopharmacology. Program Book, 165th Annual Meeting, American Psychiatric Association, 2011: Master Course 5, p.114.

A-268. Schatzberg AF. Mineralocorticoid receptor function in depression: new findings using neuroimaging and cognitive testing. Abstracts of the 24th ECNP Congress, 2011:S.16.05.

A-269. Schatzberg AF, Binder E, Nemeroff C, Schaefer T, Bol K, Haazen L, DeChaffoy D, Buntinx E. Interaction of pampamperone, citalopram and genetic variables in the prediction of antidepressant response. Abstracts of the 24th ECNP Congress, 2011:P.2.a.018.

A-270. Schatzberg AF. Cortisol in depressive subtypes: status of glucocorticoid antagonists. 15th World Congress of Psychiatry Abstract Book, Buenos Aires, Argentina, 2011:RS61.3.

A-271. Schatzberg AF, Ketter T, Chang K, Rason N, DeBattista C, Glick I. Course 8: Essential Psychopharmacology. 63rd Institute on Psychiatric Services Program Book, 2011: p.51.

A-272. Schatzberg AF. Using biological and cognitive measures to discriminate among depressive subtypes. Abstracts of the ACNP 50th Annual Meeting, 2011:S2.

A-273. Turner CA, Bunney WE, Schatzberg AF, Barchas JD, Myers RM, Jones EG, Akil H, Watson, SJ, Jr. Vipri gene expression is increased in post-mortem hippocampus of individuals with major depressive disorder. Abstracts of the ACNP 50th Annual Meeting, 2011:S137.

A-274. Lyons DM, Buckmaster CL, Schatzberg AF. Novelty seeking mediates early life effects on psychostimulant place preference conditioning in monkeys. Abstracts of the ACNP 50th Annual Meeting, 2011:S327.

- A-275. Sudheimer K, Keller J, Schatzberg AF. Abnormal hypothalamus functional connectivity in psychotic major depression. Abstracts of the ACNP 50th Annual Meeting, 2011:S400.
- A-276. Schatzberg AF, Kalin NH, Pandey GN, Belanoff JK. Genetic variation and HPA axis activity: implications for diagnosis and treatment. Abstracts of the 42nd Annual ISPNE Meeting, 2012.
- A-277. Schatzberg AF, DeBattista C. Master course 4: Essential psychopharmacology. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2012:37.
- A-278. Schatzberg AF, Kalin NH. Can major depression be prevented? New insights from basic and clinical studies. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2012:S024-4, p.187.
- A-279. Schatzberg AF. Stress inoculation and resilience in a primate model. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2012:S025-2, p.188.
- A-280. Schatzberg AF. Combining pharmacotherapy with other modalities. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2012:S081-1, p.295.
- A-281. Schatzberg AF. HPA axis activity, genetic variation, and psychosis in major depression. Syllabus Book, 165th Annual Meeting, American Psychiatric Association, 2012:S106-2, p.343.
- A-282. Frank E, Csernansky JG, Davis KL, Goldman HH, Potter WZ, Schatzberg AF. Possible in the the second decade of the 21st century? Abstracts of the ACNP 51st Annual Meeting, 2012:S12.
- A-283. Sudheimer K, Keller J, Tennakoon L, Schatzberg AF. Circadian cortisol and hypothalamic-subgenual cortex functional connectivity in major depression with and without psychotic features. Abstracts of the ACNP 51st Annual Meeting, 2012:S156.
- A-284. Burmeister M, Stumba V, Keller B, Schmidt E, Flickinger M, Sliweska E, Schatzberg AF, Barchas J, Bunney WE, Myers RM, Watson SJ, Li J, Scott L, Boehnke M, Akil H. eQTLs are conserved across brain regions and inform genetic association results of bipolar depression. Abstracts of the ACNP 51st Annual Meeting, 2012:S217.
- A-285. Nechvatal JM, Qui D, Buckmaster CL, Schatzberg AF, Moseley ME, Lyons DM. Early life stress inoculation changes brain development. Abstracts of the Society of Biological Psychiatry 68th Annual Scientific Convention & Meeting, Biol Psychiatry 2013; 73: 84S.
- A-286. Schatzberg AF. Genetic variation and HPA axis activity: implications for risk for depression and psychosis. Abstracts of the Society of Biological Psychiatry 68th Annual Scientific Convention & Meeting, Biol Psychiatry 2013; 73: 243-244S.

A-287. Schatzberg AF. ABCB-1: Antidepressant response in geriatric depression and chronic depression. Abstracts of the Society of Biological Psychiatry 69th Annual Scientific Convention Program, *Biol Psychiatry* 2014; 75: 70S.

A-288. Young CB, Nusslock R, Keller J, Schatzberg AF, Menon V. Cortico-limbic-striatal reactivity in depression and its relationship with anhedonia. Abstracts of the Society of Biological Psychiatry 69th Annual Scientific Convention Program, *Biol Psychiatry* 2014; 75: 688S.

A-289. Schatzberg AF. The HPA axis in psychotic depression. Abstracts of the Society of Biological Psychiatry 70th Annual Scientific Convention Program, *Biol Psychiatry* 2015; 77: 143S.

A-290. Schatzberg AF. CRH-R1 variation and measures of depression and psychosis. Abstracts of the Society of Biological Psychiatry 70th Annual Scientific Convention Program, *Biol Psychiatry* 2015; 77: 155S.

A-291. Goldstein-Piekarski AN, Yesavage J, Schatzberg AF, Etkin A, O'Hara R, Suppes T, Korgaonkar, Williams L. Personalizing the treatment of depression: emotional reactivity and early life stress predict anti-depressant outcomes. Abstracts of the Society of Biological Psychiatry 70th Annual Scientific Convention Program, *Biol Psychiatry* 2015; 77: 243S.

A-292. Sudheimer K, Keller J, O'Hara R, Schatzberg AF. Genetic variations in the glucocorticoid and mineralocorticoid receptor genes are associated with disrupted hypothalamic functional connectivity and elevated nocturnal cortisol secretion in depression. Abstracts of the Society of Biological Psychiatry 70th Annual Scientific Convention Program, *Biol Psychiatry* 2015; 77: 258S.

Original Reports (Journals)

1. Schatzberg AF, Reich W. Self-destined victim and social casualty. *Arch Gen Psychiatry* 1972; 27:73-77.
2. Khantzian EJ, Mack JE, Schatzberg AF. Heroin use as an attempt to cope: Clinical observations. *Am J Psychiatry* 1974; 131:160-164.
3. Nicholson PT, Mirin SM, Schatzberg AF. Ineffective military personnel: An ethical integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia.dilemma for psychiatry. *Arch Gen Psychiatry* 1974; 30(3):406-410.
4. Schatzberg AF, Lobis RA, Westfall MP. The use of psychodrama in the hospital setting. *Am J Psychotherapy* 1974; 27:553-565.
5. Schatzberg AF, Westfall MP, Blumetti AF, Birk CL. Effeminacy I: A quantitative rating scale. *Arch Sex Beh* 1975; 4:31-41.
6. Westfall MP, Schatzberg AF, Blumetti AB, Birk CL. Effeminacy II: Variation with social context. *Arch Sex Beh* 1975; 4:43-51.

7. Schatzberg AF. Drug management of treatment-resistant depression. *McLean Hospital J* 1976; 1:89-101.
8. Cole JO, Schatzberg AF. Memory difficulty and tricyclic antidepressants. *McLean Hosp J*. 1976; 1:102-107.
9. Schildkraut JJ, Roffman M, Orsulak PJ, Schatzberg AF, Kling AA, Reigle RG. Effects on short- and long-term administration of tricyclic antidepressants and lithium on norepinephrine turnover in brain. *Pharmakopsychiatrie-Neuropsychopharmacologie* 1976; 9:193-202.
10. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Cole JO, Gudeman JE, Rohde WA. Elevated platelet monoamine oxidase (MAO) activity in schizophrenia-related depressive disorders. *Am J Psychiatry* 1978; 135:110-112.
11. Schatzberg AF, Cole JO, Blumer DP. Speech blockage: A tricyclic side effect. *Am J Psychiatry* 1978; 135:600-601.
12. Schatzberg AF. Benzodiazepines in depressive disorders: A clinical guide. *South Med J* 1978; 71(Suppl 2):18-22.
13. McCurdy L, Schatzberg AF. Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology. *J Clin Psychiatry* 1978; 39(Suppl):30-34.
14. Schatzberg AF, Cole JO. Benzodiazepines in depressive disorders. *Arch Gen Psychiatry* 1978; 35:1359-1365.
15. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Towards a biochemical classification of depressive disorders I: Differences in urinary MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. *Arch Gen Psychiatry* 1978; 35:1427-1433.
16. Schildkraut JJ, Orsulak PJ, LaBrie RA, Schatzberg AF, Gudeman JE, Cole JO, Rohde WA. Towards a biochemical classification of depressive disorders II: Application of multiple discriminant function analysis to data on urinary catecholamines and metabolites. *Arch Gen Psychiatry* 1978; 35:1436-1439.
17. Orsulak PJ, Schildkraut JJ, Schatzberg AF, Herzog JM. Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders. *Biol Psychiatry* 1978; 13:637-647.
18. Schatzberg AF. Anxiety disorders: Classification and differential diagnosis. *McLean Hospital J* 1978; 3(Suppl.):16-27.
19. Schatzberg AF, Orsulak PJ, Rosenbaum AH, Kruger ER, Schildkraut JJ, Cole JO. Catecholamine measures for diagnosis and treatment of patients with depressive disorders. *J Clin Psychiatry* 1980; 41:35-39.

20. Rosenbaum AH, Schatzberg AF, Maruta T, Orsulak PJ, Cole JO, Grab EL, Schildkraut JJ. MHPG as a predictor of antidepressant response to imipramine and maprotiline. *Am J Psychiatry* 1980; 137:1090-1092.
21. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Herzog JM. Platelet monoamine oxidase activity in subgroups of schizophrenic disorders. *Schizophrenia Bull* 1980; 6:220-225.
22. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Cole JO, Rosenbaum AH. Possible pathophysiological mechanisms in subtypes of unipolar depressive disorders based on differences in urinary MHPG levels. *Psychopharm Bull* 1980; 17:90-91.
23. Schatzberg AF, Orsulak PJ, Rosenbaum AH, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders IV: Pretreatment urinary MHPG levels as predictors of response to imipramine. *Communications in Psychopharmacology* 1980-1981; 4:441-445.
24. Schatzberg AF, Cole JO. Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. *Br J Clin Pharm* 1981; 11:17S-22S.
25. Mirin SM, Schatzberg AF, Creasey DE. Hypomania and mania after withdrawal of tricyclic antidepressants. *Am J Psychiatry* 1981; 138:87-89.
26. Schatzberg AF, Rosenbaum AH. Studies on MHPG levels as predictors of antidepressant response. *McLean Hosp J*. 1981; 6:138-147.
27. Cole JO, Schatzberg AF, Sniffin C, Zolner J, Cole JP. Trazodone in treatment-resistant depression. An open study. *J Clin Psychopharm* 1981; 1(Suppl 6):49S-54S.
28. Schatzberg AF, Rosenbaum AH, Orsulak PJ, Rohde WA, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotiline. *Psychopharmacology* 1981; 75:34-38.
29. Rothschild AJ, Schatzberg AF. Fluctuating postdexamethasone cortisol levels in a patient with melancholia. *Am J Psychiatry* 1982; 139:129-130.
30. Schatzberg AF, Orsulak PJ, Rosenbaum AH, Maruta T, Kruger ER, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders V: Heterogeneity of unipolar depressions. *Am J Psychiatry* 1982; 139:471-475.
31. Gudeman JE, Schatzberg AF, Samson JA, Orsulak PJ, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders VI: Platelet MAO activity and clinical symptoms in depressed patients. *Am J Psychiatry* 1982; 139:630-633.
32. The Oxaprotiline Study Group: A double-blind comparative study of oxaprotiline with amitriptyline and placebo in moderate depression. *Curr Ther Res* 1982; 32:247-256.

33. Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. *Br J Psychiatry* 1982; 141:471-474.
34. Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, MacLaughlin RA, Sullivan MA, Cole JO. The dexamethasone suppression test: identification of subtypes of depression. *Am J Psychiatry* 1983; 140:88-91.
35. Rosenbaum AH, Maruta T, Schatzberg AF, Orsulak PJ, Jiang N-S, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders VII: Urinary free cortisol and urinary MHPG in depressions. *Am J Psychiatr.* 1983; 140:314-318.
36. de la Fuente JR, Rosenbaum AH, Morse RM, Niven RG, Abboud CF, Juang N-S, Schatzberg AF. The hypothalamic-pituitary-adrenal axis in alcoholics. *Alcoholism: Clin and Exper Res* 1983; 7:35-37.
37. Rosenbaum AH, Schatzberg AF, Jost FA, Cross PD, Wells LA, Juang N-S, Maruta T. Urinary free cortisol levels in anxiety. *Psychosomatics* 1983; 24:835-837.
38. Schatzberg AF, Orsulak PJ, Rothschild AJ, Salomon MS, Lerbinger J, Kizuka PP, Cole JO, Schildkraut JJ. Platelet MAO activity and the dexamethasone suppression test in depressed patients. *Am J Psychiatry* 1983; 140:1231-1233.
39. Schatzberg AF. Discussion: Controversies in antidepressant therapy. *J Clin Psychiatry* 1983; 44 (Sept, Sec. 2):29-30.
40. The Oxaprotaline Study Group: Comparative anticholinergic activity of oxaprotiline and amitriptyline. *Drug Dev Res* 1983; 3:561-566.
41. Schatzberg AF, Liptzin B, Satlin A, Cole JO. Diagnosis of affective disorders in the elderly. *Psychosomatics* 1984; 25:126-131.
42. Schatzberg AF, Rothschild AJ, Bond TC, Cole JO. The DST in psychotic depression: Diagnostic and pathophysiologic implications. *Psychopharmacol Bull* 1984; 20:362-364.
43. Langlais PJ, Rothschild AJ, Schatzberg AF, Cole JO, Bird ED. Dexamethasone elevates dopamine in human plasma and rat brain. *Psychopharmacol Bull* 1984; 20:365-370.
44. Rothschild AJ, Langlais PJ, Schatzberg AF, Walsh FX, Cole JO, Bird ED. Dexamethasone increases plasma free dopamine in man. *J Psychiatric Res* 1984; 18:217-223.
45. Hudson JI, Hudson MS, Rothschild AJ, Vignati L, Schatzberg AF, Melby JC. Abnormal dexamethasone suppression test in nondepressed patients with diabetes. *Arch Gen Psychiatry.* 1984; 41:1086-1089.

46. Rosenbaum AH, Schatzberg AF, MacLaughlin RA, Snyder K, Jiang N-S, Ilstrup D, Rothschild AJ, Klineman B. The dexamethasone suppression test in normal control subjects: Comparison of two assays and effect of age. *Am J Psychiatry* 1984; 141:1550-1555.
47. Schatzberg AF, Rothschild AJ. Discussion of controversies in psychiatry: Depression in the medically ill, sleep disorders in the elderly, and the DST. *J Clin Psychiatry* 1985; 46, 2 (Sec. 2):30-31.
48. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis of psychotic depression and related states. *J Psychiatric Res* 1985; 19:57-64.
49. Mooney JJ, Schatzberg AF, Cole JO, Kizuka PP, Schildkraut JJ. Enhanced signal transduction by adenylate cyclase in platelet membranes of patients showing antidepressant responses to alprazolam. *J Psychiatric Res* 1985; 19:65-75.
50. Rothschild AJ, Langlais PJ, Schatzberg AF, Miller MM, Salomon MS, Lerbinger JE, Cole JO, Bird ED. The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. *Life Sci* 1985; 36:2491-2501.
51. Schatzberg AF, Rothschild AJ, Gerson B, Lerbinger JE, Schildkraut JJ. Toward a biochemical classification of depressive disorders IX: DST results and platelet MAO activity. *Br J Psychiatry* 1985; 146:633-637.
52. Mooney JJ, Cole JO, Schatzberg AF, Schildkraut JJ. Pretreatment urinary MHPG levels as predictors of antidepressant responses to alprazolam. *Am J Psychiatry* 1985; 142:366-367.
53. Samson JA, Gudeman JE, Schatzberg AF, Kizuka PP, Orsulak PJ, Cole JO, Schildkraut JJ. Towards a biochemical classification of depressive disorders VIII: Platelet MAO activity in subtypes of depression. *J Psychiatric Res* 1985; 19:547-555.
54. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression: A perspective on seizures. *Arch Gen Psychiatry* 1986; 43:86-90.
55. Bond TC, Rothschild AJ, Lerbinger JE, Schatzberg AF. Delusional depression, family history, and DST response: A pilot study. *Biol Psychiatry* 1986; 21:1239-1246.
56. Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions, I: Comparison of plasma catecholamines and cortisol measures. *Psychiatry Res* 1987; 20:143-153.
57. Schatzberg AF, Rothschild AJ, Langlais PJ, Lerbinger JE, Schildkraut JJ, Cole JO. Psychotic and nonpsychotic depressions, II: Relationships among platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms. *Psychiatry Res* 1987; 20:155-164.
58. Schatzberg AF. Trazodone: A five year review of antidepressant efficacy. *Psycho-pathology* 1987; 20:48-56.

59. Schatzberg AF, Dessain E, O'Neil P, Katz DL, Cole JO. Recent studies on selective serotonergic antidepressants: Trazodone, fluoxetine, and fluvoxamine. *J Clin Psychopharmacology* 1987; 7(Suppl 6):44S-49S.
60. Mooney JJ, Schatzberg AF, Cole JO, Kizuka PP, Salomon M, Lerbinger JE, Pappalardo KM, Gerson B, Schildkraut JJ. Rapid antidepressant response to alprazolam in depressed patients with high catecholamine output and heterologous desensitization of platelet adenylate cyclase. *Biol Psychiatry* 1988; 23:543-559.
61. Schatzberg AF, Samson JA, Bloomingdale KL, Orsulak PJ, Gerson B, Kizuka PP, Cole JO, Schildkraut JJ. Toward a biochemical classification of depressive disorders, X: Urinary catecholamines, their metabolites, and D-type scores in sub-groups of depressive disorders. *Arch Gen Psychiatry* 1989; 46:260-268.
62. Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, Samson JA, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. *Biol Psychiatry* 1989; 26:565-575.
63. Teicher MH, Glod CA, Aaronson ST, Gunter PA, Schatzberg AF, Cole JO. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. *Psychopharm Bull* 1989; 25:535-550.
64. Schatzberg AF, Samson JA, Rothschild AJ, Luciana MM, Bruno RF, Bond TC. Depression secondary to anxiety: Findings from the McLean Hospital Depression Research Facility. *Psych Clin N Amer* 1990; 13:633-649.
65. Mooney JJ, Schatzberg AF, Cole JO, Samson JA, Waternaux C, Gerson B, Pappalardo KM, Schildkraut JJ. Urinary MHPG and the D-type score as predictors of differential responses to antidepressants. *J Clin Psychopharm* 1991; 11:339-343.
66. Goldblatt MJ, Schatzberg AF. Does treatment with antidepressant medication increase suicidal behavior? *Int J Clin Psychopharm* 1991; 6:219-226.
67. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM IV? *Am J Psychiatry* 1992; 149:733-745.
68. Kane JM, Cole J, Evans DL, Fiester SJ, Mirin SM, Pincus HA, Schatzberg AF, and Popper CW. Model psychopharmacologic screening criteria. *J Clin Psychiatry* 1992; 53:184-196.
69. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamic-pituitary-adrenal axis activity and one-year outcome in depression. *Biol Psychiatry* 1993; 34:392-400.
70. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. *Psychiatry Res* 1993; 46:139-149.
71. Marcel BB, Samson J, Cole JO, Schatzberg AF. Discrimination of facial emotion in depressed patients with visual-perceptual disturbances. *J Neuro Men Dis* 1993; 181:583-584.

72. Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, Saylor M. Fluoxetine and desipramine in major depressive disorder. *J Clin Psychopharm* 1993; 13:305-311.
73. Albanese M, Bartel R, Bruno R, Morgenbesser MW, Schatzberg AF. Comparison of measures used to determine substance abuse in an inpatient psychiatric population. *Am J Psychiatry* 1994; 151:7:1077-1078.
74. DeBattista D, Schatzberg AF. An algorithm for the treatment of major depression and its subtypes. *Psychiatric Annals* 1994; 24:341-347.
75. Posener JA, Schildkraut JJ, Williams GH, Gleason RE, Salomon MS, Mecheri G, Schatzberg AF. Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. *Biol Psychiatry* 1994; 36:616-621.
76. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. *J Clin Psychopharm* 1995; 15:23-29.
77. Posener JA, Schildkraut JJ, Williams GH, Gleason RE, Salomon MS, Schatzberg AF. Acute and delayed effects of adrenocorticotrophic hormone on dopamine activity in man. *Depression* 1995; 2:292-296.
78. Kornstein SG, Schatzberg AF, Yonkers KA, Thase ME, Ketner GI, Ryan CE, Schlager D. Gender Differences in Presentation of Chronic Major Depression. *Psychopharm Bull* 1995; 31:711-718.
79. Keller MB, Harrison W, Fawcett JA, Gelenberg A, Klein D, Kocsis J, McCullough JP, Rush AJ, Schatzberg AF, Thase M. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. *Psychopharm Bull* 1995; 31:205-212.
80. Posener JA, Schildkraut JJ, Samson JA, Schatzberg AF. Diurnal variation of plasma cortisol and homovanillic acid in healthy subjects. *Psychoneuroendocrinology* 1996; 21:33-38.
81. Schatzberg AF. Course of depression in adults: treatment options. *Psychiatric Annals* 1996; 26:336-341.
82. Schatzberg AF, DeBattista C, DeGolia S. Valproate in the treatment of agitation associated with depression. *Psychiatric Annals* 1996; 26 (Suppl):S470-S473.
83. DeBattista C, Schatzberg AF. New options in the pharmacotherapy for geriatric depression. *Clin Geriatrics* 1996; 4:29-43.
84. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. *JAMA* 1996; 276(4):313-318.

85. Shiang J, Blinn R, Bongar, B, Stephens B, Allison D, Schatzberg A. Suicide in San Francisco, CA: A comparison of Caucasian and Asian groups, 1987-1994. *Suicide and Life-threatening Behavior* 1997; 27:80-91.
86. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo Biloba for dementia. *JAMA* 1997; 278:1327-1332.
87. Schatzberg AF. Introduction. Antidepressant discontinuation syndrome: An update on serotonin reuptake inhibitors. *J Clin Psychiatry* 1997; 58(Suppl 7):3.
88. Schatzberg AF, Haddad P, Kaplan ER, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. *J Clin Psychiatry* 1997; 58(Suppl 7):5-10.
89. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. *J Clin Psychiatry* 1997; 58(Suppl 7):23-27.
90. Posener JA, Schildkraut JJ, Williams GH, Schatzberg AF. Cortisol feedback effects on plasma corticotropin levels in health subjects. *Psychoneuroendocrinology* 1997; 22:169-176.
91. Posener JA, Schildkraut JJ, Williams GH, Schatzberg AF. Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in human subjects. *Psychoendocrinology* 1998; 23:371-383.
92. Regier DA, Rac DS, Narrow WE, Kaelber CT, Schatzberg AF. The prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. *Br J Psychiatry* 1998; 173 (Suppl 34):24-28.
93. Schatzberg AF, Samson JA, Rothschild AJ, Bond TC, Regier DA. McLean Hospital Depression Research Facility: Early onset phobic disorders and adult onset major depression. *Br J Psychiatry* 1998; 173 (Suppl 34):29-34.
94. Miller IW, Keitner GI, Schatzberg AF, Klein D, Thase ME, Rush AJ, Markowitz JC, McCullough J, Kornstein SG, Davis SM, Harrison W, Keller MB. Psychosocial functioning of chronically depressed patients before and after treatment with sertraline or imipramine. *J Clin Psychiatry* 1998; 59:608-619.
95. Rush AJ, Koran LM, Keller MB, Markowitz JC, Gelenberg AJ, Hirschfeld RMS, Klein DN, McCullough JP, Schatzberg AF, et al. The treatment of chronic depression, Part I: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. *J Clin Psychiatry* 1998; 59:589-597.
96. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg AF, Russell J, Hirschfeld R, Klein D, Fawcett JA, Kornstein S, LaVange L, Harrison W. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. *JAMA* 1998; 280:1665-1672.

97. Miller TP, Taylor J, Rogerson S, Mauricio Maritess, Kennedy Q, Schatzberg AF, Tinklenberg J, and Yesavage J. Cognitive and noncognitive symptoms in dementia patients: Relationship to cortisol and dehydroepiandrosterone. *International Psychogeriatrics* 1998; 10(1):85-96.
98. DeBattista C, Sofuoglu M, Schatzberg AF. Serotonergic synergism: The risks and benefits of combining the SSRI's with other serotonergic drugs. *Biol Psychiatry* 1998; 44:341-347.
99. Lyons DM, Kim S, Schatzberg AF, Levine S. Postnatal foraging demands alter adrenocortical activity and psychosocial development. *Developmental Psychobiology* 1998; 32:285-291.
100. Lyons DM, Wang OJ, Lindley SE, Levine S, Kalin NH, and Schatzberg AF. Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resembles aspects of hypercortisolism in humans. *Psychoneuroendocrinology* 1999; 24:131-140.
101. Posener JA, Schatzberg AF, Williams GH, Samson JA, McHale NL, Bessette MP, Schildkraut JJ. Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. *Biol Psychiatry* 1999; 45:222-228.
102. Klein DN, Schatzberg AF, McCullough J, Dowling F, Goodman D, Howland R, Markowitz J, Smith C, Thase M, Rush J, LaVange L, Harrison WM, Keller M. Early-versus late-onset dysthymic disorder: comparison in outpatients with superimposed major depressive episodes. *J Affective Disorders* 1999; 52:187-196.
103. Lindley SE, Bengoechea GT, Wong DL, Schatzberg AF. Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. *Brain Research* 1999; 832:152-158.
104. Martel FL, Hayward C, Lyons DM, Sanborn K, Varady S, Schatzberg AF. Salivary cortisol levels in socially phobic adolescent girls. *Depression and Anxiety* 1999; 10:25-27.
105. Lyons DM, Martel FL, Levine S, Risch NJ, Schatzberg AF. Postnatal experiences and genetic effects on squirrel monkey social affinities. *Hormones and Behavior*. 1999; 36:266-275.
106. Klein DN, Schatzberg AF, McCullough JP, Keller MB, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Miceli R, Harrison WM. Age of onset in chronic major depression: Relation to demographic and clinical variables, family history, and treatment response. *J Affective Disorders* 1999; 55:149-157.
107. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL, Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. *Neuropsychopharmacology* 1999; 21:399-407.
108. Schatzberg AF, DeBattista C. Phenomenology and Treatment of Agitation. *J Clin Psychiatry* 1999; 60 (Suppl 15):17-20.

109. Tolwani RJ, Waggle KS, Green SL, Tolwani AJ, Lyons DM, Schatzberg AF. Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey. *J Medical Primatology* 2000; 29:42-45.
110. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi ME, Zajecka J, Schatzberg AF. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *New England J of Med* 2000; 342:1462-1470.
111. Hirschfeld RMA, Montgomery SA, Keller M, Kasper S, Schatzberg A, Moeller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois ML. Social functioning in depression: a review. *J Clin Psychiatry* 2000; 61:268-275.
112. Patel PD, Lyons DM, Zhang Z, Ngo H, Schatzberg AF. Impaired transactivation of the glucocorticoid receptor cloned from the Guyanese squirrel monkey. *J Steroid Biochemistry & Mol Biol* 2000; 72:115-123.
113. Posener JA, DeBattista C, Williams GH, Kraemer HC, Kalehzan BM, Schatzberg AF. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. *Arch Gen Psychiatry* 2000; 57:755-760.
114. DeBattista D, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of IV hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study. *Am J Psychiatry* 2000; 157:1334-1337.
115. Schatzberg AF, Posener JA, DeBattista C, Rothschild AJ, Kalehzan BM, Shear P. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. *Am J Psychiatry* 2000; 157:7; 1095-1100.
116. Hayward C, Varady S, Albano AM, Thienemann M, Henderson L, Schatzberg AF. Cognitive-behavioral group therapy for social phobia in female adolescents. Results of a pilot study, *J Am Acad Child Adolesc Psychiatry* 2000; 39:721-726.
117. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. *Am J Psychiatry* 2000; 157: 982-986.
118. Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A. Nicotine patch and paroxetine for smoking cessation. *J Consul and Clin Psych* 2000; 68:883-889.
119. Lyons DM, Yang C, Mobley BW, Nickerson JT, Schatzberg AF. Early environmental regulation of glucocorticoid feedback sensitivity in young adult monkeys. *J Neuroendocrinology* 2000; 12:723-728.
120. Lyons DM, Lopez JM, Yang C, Schatzberg AF. Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys. *J Neurosci.* 2000; 20:7816-7821.
121. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. *Biol Psychiatry.* 2000; 47:736-744.

122. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison WM, Davis SM, Keller MR. Gender differences in chronic major and double depression. *J Affective Disorders* 2000; 60:1-11.
123. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. *Am J Psychiatry* 2000; 157:1445-1452.
124. DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. *J Clin Psychopharmacol.* 2000; 20:274-275.
125. Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. *J Affect Disord* 2000; 59 Suppl 1:S39-S56.
126. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. *J Psych Res* 2000; 34:383-392.
127. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RMA, LaVange LM, Keller MB. Sertraline vs. imipramine to prevent relapse in chronic depression. *J Affective Disorders.* *J Affective Disorders* 2001, 65:27-36.
128. Belanoff J, Flores B, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. *J Clin Psychopharmacol* 2001; 21:516-521.
129. Belanoff J, Gross K, Yager A, Schatzberg AF. Corticosteroids and cognition. *J Psych Res* 2001; 35:127-145.
130. Belanoff J, Kalezhan M, Sund B, Fleming Ficek S, Schatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. *Am J Psychiatry.* 2001; 158:1612-1616.
131. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). *J Clin Endocrinol Metab* 2001; 86:3568-3573.
132. Claassen JD, Pascoe N, Schatzberg AF, Murphy GM Jr. Rapid detection of the C-1496G polymorphism in the CYP2D6 *2 allele. *Clin Chem* 2001; 47:2153-2155.
133. Posener JA, DeBattista C, Williams GH, Schatzberg AF. Cortisol feedback during the HPA quiescent period in patients with major depression. *Am J Psychiatry* 2001; 158:2083-2085.

134. Lyons DM, Yang C, Sawyer-Glover AM, Moseley ME, Schatzberg AF. Early life stress and inherited variation in monkey hippocampal volumes. *Arch Gen Psychiatry* 2001; 58:1145-1151.
135. Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. *Addictive Behaviors* 2001; 27:1-10.
136. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Sertraline versus imipramine to prevent relapse in chronic depression. *J Affect Disord* 2001; 65:27-36.
137. Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs. placebo. *Arch Gen Psychiatry* 2002; 59:723-728.
138. Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz JC, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. *Biol Psychiatry* 2002; 51:123-133.
139. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. *Arch Gen Psychiatry* 2002; 59:233-239.
140. Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, Borenstein M, Bowden CL, Caplan A, Emslie GJ, Evans DL, Geller B, et al; Consensus Development Panel. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. *Arch Gen Psychiatry* 2002; 59:262-270.
141. Menon V, Boyett-Anderson JM, Schatzberg AF, Reiss AL. Relating semantic and episodic memory systems. *Brain Res Cogn Brain Res* 2002; 13:261-265.
142. Thase ME, Rush AJ, Manber R, Kornstein SG, Klein DN, Markowitz JC, Ninan PT, Friedman ES, Dunner DL, Schatzberg AF, Borian FE, Trivedi MH, Keller MB. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. *J Clin Psychiatry* 2002; 63:493-500.
143. Kupfer DJ, Hyman SE, Schatzberg AF, Pincus HA, Reynolds CF 3rd. Recruiting and retaining future generations of physician scientists in mental health. *Arch Gen Psychiatry* 2002; 59:657-660.

144. Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. *J Mol Neurosci* 2002; 19:201-206.
145. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr; The Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. *Am J Geriatr Psychiatry* 2002; 10:541-550.
146. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. *Biol Psychiatry* 2002; 52:386-392.
147. Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, B Innis RB, Killen J, Laughren TP, McDonald WM, M Murphy GM Jr, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T. Developing novel treatments for mood disorders: accelerating discovery. *Biol Psychiatry* 2002; 52:589-609.
148. Lyons DM, Afarian H, Schatzberg AF, Sawyer-Glover A, Moseley ME. Experience-dependent asymmetric variation in primate prefrontal morphology. *Behav Brain Res* 2002; 136:51-59.
149. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. *Am J Psychiatry* 2002; 159:1855-1861.
150. DeBattista C, Rothschild AJ, Schatzberg AF. A dynamic algorithm for the treatment of psychotic major depression. *Psychiatr Ann* 2002; 32:681-691.
151. Hypericum Depression Trial Study Group: Effect of hypericum perforatum (St. John's wart) in major depression: a randomized controlled trial. *JAMA* 2002; 287:1807-1814.
152. Schatzberg AF, DeBattista C. Current psychotropic dosing and monitoring guidelines: 2002. *Primary Psychiatry* 2002; 9:34-48.
153. Lindley SE, Bengoechea TG, Wong DL, Schatzberg AF. Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. *Brain Res* 2002; 958:414-422.
154. Schatzberg AF. Pharmacological principles of antidepressant efficacy. *Hum Psychopharmacol* 2002; 17 Suppl 1:S17-22.
155. McDonald WM, Salzman C, Schatzberg AF. Depression in the elderly. *Psychopharmacol Bull* 2002; 36 Suppl 2:112-122.
156. Schatzberg AF. Brain imaging in affective disorders: more questions about causes versus effects. *Am J Psychiatry* 2002; 159(11):1807-1808.
157. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV. Duloxetine for the treatment of major depressive disorder. *Psychopharm Bull* 2002; 36: 106-132.

158. Greicius MD, Krasnow B, Boyett-Anderson JM, Eliez S, Schatzberg AF, Reiss AL, Menon V. Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. *Hippocampus*. 2003; 13:164-174.
159. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. *Arch Gen Psychiatry* 2003; 60:39-47.
160. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. *Horm Behav* 2003; 43:60-66.
161. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharmacol* 2003; 23:27-30.
162. Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. *J Clin Psychiatry* 2003; 64:321-330.
163. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF, and the Mirtazapine versus Paroxetine Study Group. The apolipoprotein E ϵ 4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. *Biol Psychiatry* 2003; 54: 665-674.
164. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr., Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. *Proceedings of National Academy of Sciences* 2003; 100(24): 14293-14296.
165. Boyett-Anderson JM, Lyons DM, Reiss AL, Schatzberg AF, Menon V. Functional brain imaging of olfactory processing in monkeys. *Neuroimage* 2003; 20(1): 257-264.
166. Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. *Am J Psychiatry* 2003; 160(10): 1830-1835.
167. Lyons DM, Schatzberg AF. Early maternal availability and prefrontal correlates of reward-related memory. *Neurobiol Learn Mem* 2003; 80(2): 97-104.
168. Schatzberg AF. Efficacy and Tolerability of Duloxetine, a Novel Dual Reuptake Inhibitor, in the Treatment of Major Depressive Disorder. *J Clin Psychiatry* 2003; Suppl 13:30-37.
169. Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. *J Clin Psychiatry* 2004; 65 Suppl 15:15-20.
170. Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Prospective investigation of stress inoculation in young monkeys. *Arch Gen Psychiatry* 2004; 61(9):933-941.

171. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Samuels D, Schatzberg AF. Major depression among adolescent smokers undergoing treatment for nicotine dependence. *Addict Behav* 2004; 29(8):1517-1526.
172. Murphy GM, Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. *Arch Gen Psychiatry* 2004; 61(11):1163-1169.
173. Schatzberg AF. The relationship of chronic pain and depression. *J Clin Psychiatry* 2004; 65 Suppl 12:3-4.
174. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, Schatzberg AF. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. *J Consult Clin Psychol* 2004; 72(4):729-735.
175. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. *J Clin Psychopharmacol* 2004; 24(4):365-373.
176. Posener JA, Charles D, Veldhuis JD, Province MA, Williams GH, Schatzberg AF. Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder. *Psychoneuroendocrinology* 2004; 29(9):1129-1137.
177. Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, Zubieta JK. HPA axis activation in major depression and response to fluoxetine: a pilot study. *Psychoneuroendocrinology* 2004; 29(9):1198-1204.
178. Lyons DM, Yang C, Eliez S, Reiss AL, Schatzberg AF. Cognitive correlates of white matter growth and stress hormones in female squirrel monkey adults. *J Neurosci* 2004; 24(14):3655-3662.
179. Schatzberg AF. Pharmacologic treatments of major depression: are two mechanisms really better than one? *J Clin Psychiatry* 2004; 65 Suppl 4:3-4.
180. Schatzberg AF. Non-schizophrenic psychoses: common and distinguishing features. *J Psychiatr Res* 2004; 38(1):1-2.
181. Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. *J Psychiatr Res* 2004; 38(1):27-35.
182. Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. *J Clin Psychopharmacol* 2005; 25(4 Suppl 1):S1-7.
183. Lindley SE, She X, Schatzberg AF. Monoamine oxidase and catechol-o-methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids. *Psychoneuroendocrinology* 2005; 30(8):785-790.

184. Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. *Psychoneuroendocrinology* 2005; 30(9):924-929.
185. Buckley TM, Schatzberg AF. Aging and the role of the HPA axis and rhythm in sleep and memory-consolidation. *Am J Geriatr Psychiatry* 2005; 13(5):344-352.
186. Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. *Arch Gen Psychiatry* 2005; 62(5):513-20.
187. Her S, Patel PD, Schatzberg AF, Lyons DM. Mutations in squirrel monkey glucocorticoid receptor impair nuclear translocation. *J Steroid Biochem Mol Biol* 2005; 94(4):319-26.
188. Parker KJ, Buckmaster CL, Justus KR, Schatzberg AF, Lyons DM. Mild early life stress enhances prefrontal-dependent response inhibition in monkeys. *Biol Psychiatry* 2005; 57(8):848-855.
189. Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. *J Clin Endocrinol Metab* 2005; 90(5):3106-3114.
190. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. *J Psychiatr Res* 2005; 39(1):43-53.
191. O'Hara R, Schroder CM, Kraemer HC, Kryla N, Cao C, Miller E, Schatzberg AF, Yesavage JA, Murphy GM Jr. Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. *Neurology* 2005; 65(4):642-644.
192. Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF. The efficacy of divalproex sodium in the treatment of agitation associated with major depression. *J Clin Psychopharmacol* 2005; 25(5):476-479.
193. Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG. From clinical research to clinical practice: a 4-year review of ziprasidone. *CNS Spectr.* 2005; 10(11):s1-20.
194. Belanoff JK, Sund B, Koopman C, Blasey C, Flamm J, Schatzberg AF, Spiegel D. A randomized trial of the efficacy of group therapy in changing viral load and CD4 counts in individuals living with HIV infection. *Int'l J. Psychiatry in Medicine* 2005; 35(4): 349-362.

195. Keller J, Gomez RG, Kenna HA, Poesner J, Debattista C, Flores B, Schatzberg AF. Detecting psychotic major depression using psychiatric rating scales. *J Psychiatr Res* 2006; 40(1): 22-29.
196. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. *Neuropsychopharmacology* 2006; 31(3): 628-636.
197. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams G, Schatzberg AF. Cortisol circadian rhythm alterations in psychotic major depression. *Biol Psychiatry* 2006; 60(3): 275-281.
198. Parker KJ, Buckmaster CL, Sundlass K, Schatzberg AF, Lyons DM. Maternal mediation, stress inoculation, and the development of neuroendocrine stress resistance in primates. *Proc Natl Acad Sci USA* 2006; 103(8): 3000-3005.
199. Karssen AM, Li JZ, Her S, Patel PD, Meng F, Evans SJ, Vawter MP, Tomita H, Choudary PV, Bunney WE, Jr., Jones EG, Watson SJ, Akil H, Myers RM, Schatzberg AF, Lyons DM. Application of microarray technology in primate behavioral neuroscience research. *Methods* 2006; 38(3): 227-234.
200. Schatzberg AF, Roose SA. Double-Blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. *Am J Ger Psychiatry* 2006; 14(4): 361-370.
201. Killen JD, Fortmann SP, Murphy GM, Jr., Hayward C, Arredondo C, Crompton D, Celio M, Abe L, Wang Y, Schatzberg AF. Extended treatment with bupropion SR for cigarette smoking cessation. *J Consult Clin Psychol* 2006; 74(2):286-294.
202. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. *J Clin Psychiatry* 2006; 67(Suppl 4):27-30.
203. Gomez RG, Fleming SH, Keller J, Flores B, Kenna H, Debattista C, Solvason B, Schatzberg AF. The neuropsychological profile of psychotic major depression and its relation to cortisol. *Biol Psychiatry* 2006; 60(5): 472-8.
204. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF.: Report by the ACNP Task Force on response and remission in major depressive disorder. *Neuropsychopharmacology* 2006; 31(9):1841-53.
205. Mitra R, Sundlass K, Parker KJ, Schatzberg AF, Lyons DM. Social stress-related behavior affects hippocampal cell proliferation in mice. *Physiol Behav* 2006; 89(2):123-7.
206. Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. *Biol Psychiatry* 2007; 62(5): 429-437.

207. Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD: **Dissociable intrinsic connectivity networks for salience processing and executive control.** *J. Neurosci.* 2007; 27(9): 2349-2356.
208. Buckley TM, Mullen BC, Schatzberg AF. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. *Psychoneuroendocrinology* 2007; 32(8-10): 859-864.
209. Green AI, Schatzberg AF. Joseph J. Schildkraut, 1934-2006. *Neuropsychopharmacology* 2007; 32(8):1855-1856.
210. Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. *Schizophrenia Bulletin* 2007; 33(4):877-885.
211. Kocsis JH, Thase ME, Trivedi MH, Shelton CS, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Bing Y, Ahmed S, Musnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. *J Clin Psychiatry* 2007; 68(7):1014-1023.
212. Lyons DM, Parker KJ, Zeitzer JM, Buckmaster CL, Schatzberg AF. Preliminary Evidence that Hippocampal Volumes in Monkeys Predict Stress Levels of Adrenocorticotrophic Hormone. *Biol Psychiatry* 2007; 62(10): 1171-1174.
213. Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007; 68(4):582-587.
214. Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephensen H, Schatzberg AF. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. *Arch Gen Psychiatry* 2007; 64(4):466-472.
215. O'Hara R, Schroder CM, Mahadevan R, Schatzberg AF, Lindley S, Weiner M, Kraemer HC, Noda A, Lin X, Gray HL, Hallmayer JF. Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. *Molecular Psychiatry* 2007; 12(6):544-555.
216. Ohayon MM, Schatzberg AF. Biomarkers and classifications. *J Psychiatr Res* 2007; 41(8):623-624.
217. Parker KJ, Rainwater KL, Buckmaster CL, Schatzberg AF, Lindley SE, Lyons DM. Early life stress and novelty seeking behavior in adolescent monkeys. *Psychoneuroendocrinology* 2007; 32(7):785-792.
218. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. *J Clin Psychiatry* 2007; 68(Suppl 8):26-34.

219. Karssen AM, Her S, Li JZ, Patel PD, Meng F, Bunney WE, Jones EG, Watson SJ, Akil H, Myers RM, Schatzberg AF, Lyons DM. Stress-induced changes in primate prefrontal profiles of gene expression. *Molecular Psychiatry* 2007; 12:1089-1102.
220. Keller MB, Trivedi MH, Thase ME, et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases. *Biol Psychiatry* 2007; 62(12):1371-1379.
221. Keller MB, Trivedi MH, Thase ME, et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. *J Clin Psychiatry* 2007; 68(8):1246-1256.
222. Sartorius N, Baghai TC, Baldwin DS, Barrett B, Bran U, Fleischhacker W, Goodwin G, Grunze H, Knapp M, Leonard BE, et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force based on a review of evidence. *Int J Neuropsychopharmacol* 2007; 20(Suppl 1): S1-207.
223. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzberg AF, Thase ME. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Erratum in: *Int Clin Psychopharmacol* 2008; 23(1): 61.
224. Buckley, T, Duggal, V, Schatzberg, AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. *J Clin Sleep Med* 2008; 4(3): 235-241.
225. Keller J, Shen L, Gomez RG, Garrett A, Solvason HB, Reiss A, Schatzberg AF. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. *Am J Psychiatry* 2008; 165(7): 872-880.
226. Schatzberg AF, Lindley S. Glucocorticoid antagonists in neuropsychotic disorders. *Eur J Pharmacol* 2008; 583(2-3): 358-364; Erratum 2008; 592:168.
227. Sequeira A, Meng F, Rollins B, Myers RM, Jones EG, Watson SJ, Akil H, Schatzberg AF, Barchas J, Bunney WE, Vawter MP. Coding SNPs included in exon arrays for the study of psychiatric disorders. *Mol Psychiatry* 2008; 13(4): 363-365.
228. Shao L, Martin MV, Watson SJ, Schatzberg AF, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP. Mitochondrial involvement in psychiatric disorders. *Ann Med* 2008; 40(4): 281-295.
229. Killen JD, Fortmann SP, Schatzberg, AF Arredondo C, Murphy G, Hayward C, Celio M, Cromp D, Fong D, Pandurangi M. Extended cognitive behavior therapy for cigarette smoking cessation. *Addiction* 2008; 103(8): 1381-1390.
230. Schatzberg AF, Weiss RD, Brady KT, Culpepper L. Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. *CNS Spectr* 2008; 13(4 Suppl 6): 3.

231. Trivedi MH, Kocsis JH, Thase ME, Morris DW, Wisniewski SR, Leon AC, Gelenberg AJ, Klein DN, Niederehe G, Schatzberg AF, Ninan PT, Keller MB. REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: Rationale and Design. *Psychopharmacol Bull.* 2008; 41(4): 5-33.
232. Perahia DG, Quail D, Desai D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression. *J Psychiatr Res* 2009; 43(5): 512-518.
233. Reynolds CF, 3rd, Lewis DA, Detre T, Schatzberg AF, Kupfer DJ. The future of psychiatry as clinical neuroscience. *Acad Med* 2009; 84(4): 446-450.
234. Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. *J Psychiatr Res* 2009; 43(11): 997-1002.
235. Rollins B, Martin MV, Sequeira PA, Moon EA, Morgan LZ, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Wallace DC, Bunney WE Vawter, MP. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. *PLoS ONE* 2009; 4(3): e4913.
236. Gomez RG, Posener JA, Keller J, Debattista C, Solvason B, Schatzberg AF. Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. *Psychoneuroendocrinology* 2009; 34(7): 1012-1018.
237. Amsterdam, JD, Williams, D, Michelson, D, Adler, LA, Dunner, DL, Nierenberg, AA, Reimherr, FW, Schatzberg, AF. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. *Neuropsychobiology* 2009; 59(4): 227-233.
238. Bailey, SR, Harrison, CT, Jeffery, CJ, Ammerman, S, Bryson, SW, Killen, DT, Robinson, TN, Schatzberg, AF, Killen, JD. Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? *Addict Behav* 2009; 34(12): 1017-1022.
239. Katz, M, Liu, C, Schaer, M, Parker, KJ, Ottet, MC, Epps, A, Buckmaster, CL, Bammer, R, Moseley, ME, Schatzberg, AF, Eliez, S, Lyons, DM. Prefrontal plasticity and stress inoculation-induced resilience. *Dev Neurosci* 2009; 31(4): 293-299.
240. Kupfer, DJ, Schatzberg, AF, Grochocinski, VJ, Dunn, LO, Kelley, KA, O'Hara, RM. The Career Development Institute for Psychiatry: an innovative, longitudinal program for physician-scientists. *Acad Psychiatry* 2009; 33(4): 313-318.
241. Lyons, DM, Parker, KJ, Katz, M, Schatzberg, AF. Developmental cascades linking stress inoculation, arousal regulation, and resilience. *Front Behav Neurosci* 2009; 3: 32.
242. Martin, MV, Rollins, B, Sequeira, PA, Mesen, A, Byerley, W, Stein, R, Moon, EA, Akil, H, Jones, EG, Watson, SJ, Barchas, J, DeLisi, LE, Myers, RM, Schatzberg, A, Bunney, WE, Vawter, MP. Exon expression in lymphoblastoid cell lines from

subjects with schizophrenia before and after glucose deprivation. *BMC Med Genomics* 2009; 2: 62.

243. Schatzberg, AF. Response to the presidential address. *Am J Psychiatry* 2009; 166(10): 1105-1107.

244. Schatzberg, AF. The silver lining of recent effectiveness trials. *World Psychiatry* 2009; 8(1): 30-32.

245. Scott, LJ, Muglia, P, Kong, XQ, Guan, W, Flickinger, M, Upmanyu, R, Tozzi, F, Li, JZ, Burmeister, M, Absher, D, Thompson, RC, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. *Proc Natl Acad Sci USA* 2009; 106(18): 7501-7506.

246. Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, Nierenberg A, Schatzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. *Psychiatry Research* 2010; 175(1-2): 67-73.

247. Sarginson, JE, Lazzeroni, LC, Ryan, HS, Schatzberg, AF, Murphy, GM, Jr. FKBP5 polymorphisms and antidepressant response in geriatric depression. *Am J Med Genet B Neuropsychiatr Genet* 2010; 153B(2): 554-560.

248. Zajecka J, Schatzberg, A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder. *J Clin Psychopharmacol* 2010; 30(2): 135-144.

249. Ohayon MM, Schatzberg AF. Social phobia and depression: prevalence and comorbidity. *J Psychosom Res* 2010; 68(3): 235-243.

250. Parker KJ, Kenna HA, Zeitzger JM, Keller J, Blasey CM, Amico JA, Schatzberg AF. Preliminary evidence that plasma oxytocin levels are elevated in major depression. *Psychiatry Res* 2010; 178(2): 359-362.

251. Etkin A, Prater KE, Hoeft F, Menon V, Schatzberg AF. Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. *Am J Psychiatry* 2010; 167(5): 545-554.

252. Ohayon MM, Schatzberg AF. Chronic pain and major depressive disorder in the general population. *J Psychiatr Res* 2010; 44(7): 454-461.

253. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM, Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. *Pharmacogenet Genomics* 2010; 20(8): 467-475.

254. Buckley TM, Schatzberg AF. A pilot study of the phase angle between cortisol and melatonin in major depression – a potential biomarker? *J Psychiatr Res* 2010; 44(2): 69-74.

255. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. *Scientific World Journal* 2010; 10: 321-328.
256. Bailey SR, Hammer SA, Bryson SW, Schatzberg AF, Killen JD. Using treatment process data to predict maintained smoking abstinence. *Am J Health Behav* 2010; 34(6): 801-810.
257. Lyons DM, Buckmaster PS, Lee AG, Wu C, Mitra R, Duffey LM, Buckmaster CL, Her S, Patel PD, Schatzberg AF. Stress coping stimulates hippocampal neurogenesis in adult monkeys. *Proc Natl Acad Sci USA* 2010; 107(33): 14823-14827.
258. Krolewski DM, Medina A, Kerman IA, Bernard R, Burke S, Thompson TC, Bunney WE, Jr, Schatzberg AF, Myers RM, Akil H, Jones EG, Watson SJ. Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus. *J Comp Neurol* 2010; 518(22): 4591-4611.
259. Reich J, Schatzberg A. Personality traits and medical outcome of cardiac illness. *J Psychiatr Res* 2010; 44(15): 1017-1020.
260. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul* 2010; 3(4): 187-199.
261. Killen JD, Fortmann SP, Murphy GM, Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. *Addiction* 2010; 105(9): 1660-1668.
262. Lindley S, Cacciapaglia H, Noronha D, Carlson E, Schatzberg AF. Monitoring mental health treatment acceptance and initial treatment adherence in veterans: veterans of Operations Enduring Freedom and Iraqi Freedom versus other veterans of other eras. *Ann N Y Acad Sci* 2010; 1208: 104-113.
263. Lyons DM, Parker KJ, Schatzberg AF. Animal models of early life stress: implications for understanding resilience. *Dev Psychobiol* 2010; 52(7): 402-410.
264. Lyons DM, Parker KJ, Schatzberg AF. Animal models of early life stress: implications for understanding resilience. *Dev Psychobiol* 2010; 52(7): 616-624.
265. Garrett A, Kelly R, Gomez R, Keller J, Schatzberg AF, Reiss AL. Aberrant brain activation during a working memory task in psychotic major depression. *Am J Psychiatry* 2011; 168(2): 173-182.
266. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD, Schatzberg AF, Myers RM, Akil H, Watson SJ. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. *Mol Psychiatry* 2011; 16(6): 634-646.

267. Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, Schlaepfer T, McConnachie A, Haazen L, Buntinx E. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. *Psychological Medicine* 2011; 41(10): 2089-2097.
268. Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet* 2011;43(10): 977-983.
269. Moon E, Rollins B, Mesen A, Sequeira A, Myers RM, Akil H, et al. Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population. *Schizophr Res* 2011;131(1-3): 52-57.
270. Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. *Am J Psychiatry* 2011;168(9): 968-978.
271. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B Neuropsychiatr Genet* 2011;156B(3): 275-284.
272. Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. *Trials* 2011;12:4.
273. Parker KJ, Hyde SA, Buckmaster CL, Tanaka SM, Brewster KK, Schatzberg AF, et al. Somatic and neuroendocrine responses to standard and biologically salient acoustic startle stimuli in monkeys. *Psychoneuroendocrinology* 2011; 36(4): 547-556.
274. Kessler RC, Schatzberg AF. Commentary on abortion studies of Steinberg and Finer (*Social Science & Medicine* 2011; 72:72-82) and Coleman (*Journal of Psychiatric Research* 2009; 43:770-6 & *Journal of Psychiatric Research* 2011; 45:1133-4). *J Psychiatr Res* 2012; 46(3): 410-411.
275. Che AM, Gomez RG, Keller J, Lembke A, Tennakoon L, Cohen GH, Schatzberg AF. The relationships of positive and negative symptoms with neuropsychological functioning and their ability to predict verbal memory in psychotic major depression. *Psychiatry Res* 2012; 198(1): 34-38.
276. Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J, Schatzberg AF, Watson SJ, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP. Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. *PLoS One* 2012; 7(4):e35367.

277. Fayolle G, Levick W, Lajiness-O'Neill R, Fastenau P, Briskin S, Bass N, et al. Grand rounds. *Arch Clin Neuropsychol* 2012; 27(6): 576-685.
278. Kerman IA, Bernard R, Bunney WE, Jones EG, Schatzberg AF, Myers RM, et al. Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder. *Front Neurosci* 2012; 6:135.
279. Medina A, Seasholtz AF, Sharma V, Burke S, Bunney W, Jr., Myers RM, et al. Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. *J Psychiatric Research* 2013; 47(3): 307-314.
280. Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, Kraemer FB, Schatzberg AF. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. *Psychoneuroendocrinology* 2013; 38(1): 115-121.
281. Kelley R, Garrett A, Cohen J, Gomez R, Lembke A, Keller J, Reiss AL, Schatzberg AF. Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. *Psychiatry Res* 2013; 211(2): 119-126.
282. Tomita H, Ziegler ME, Kim HB, Evans SJ, Choudary PV, Li JZ, et al. G protein-linked signaling pathways in bipolar and major depressive disorders. *Frontiers in Genetics* 2013; 4: 297.
283. Holland JM, Schatzberg AF, O'Hara R, Marquett RM, Gallagher-Thompson D. Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy. *Psychiatry Research* 2013; 210(2): 444-450.
284. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nature Genetics* 2013; 45(9): 984-994.
285. Grieve SM, Korgaonkar MS, Etkin A, Harris A, Koslow SH, Wisniewski S, et al. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. *Trials* 2013; 14: 224.
286. Guella I, Sequeira A, Rollins B, Morgan L, Torri F, van Erp TG, et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. *J Psychiatric Research* 2013; 47(9): 1215-1221.
287. Medina A, Burke S, Thompson RC, Bunney W, Jr., Myers RM, Schatzberg A, et al. Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. *J Psychiatric Research* 2013; 47(9): 1150-1156.
288. Li JZ, Bunney BG, Meng F, Hagenauer MH, Walsh DM, Vawter MP, et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. *Proceedings of the National Academy of Sciences of the United States of America* 2013; 110(24): 9950-9955.

289. Murphy GM, Jr., Sarginson JE, Ryan HS, O'Hara R, Schatzberg AF, Lazzeroni LC. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. *Pharmacogenetics and Genomics* 2013; 23(6): 301-313.
290. Cohen JD, Nichols T, Keller J, Gomez RG, Schatzberg AF, Reiss AL. Insular cortex abnormalities in psychotic major depression: relationship to gender and psychotic symptoms. *Neuroscience Research* 2013; 75(4): 331-339.
291. Holland JM, Rozalski V, Thompson KL, Tiongson RJ, Schatzberg AF, O'Hara R, et al. The unique impact of late-life bereavement and prolonged grief on diurnal cortisol. *The Journals of Gerontology Series B* 2014; 69(1): 4-11.
292. Schatzberg AF, Keller J, Tennakoon L, Lembke A, Williams G, Kraemer FB, et al. HPA axis genetic variation, cortisol and psychosis in major depression. *Mol Psychiatry* 2014; 19(2): 220-227.
293. Lee AG, Buckmaster CL, Yi E, Schatzberg AF, Lyons DM. Coping and glucocorticoid receptor regulation by stress inoculation. *Psychoneuroendocrinology* 2014; 49: 272-279.
294. Reich J, Schatzberg A. An empirical data comparison of regulatory agency and malpractice legal problems for psychiatrists. *Ann Clin Psychiatry* 2014; 26(2): 91-96.
295. Schatzberg AF. A word to the wise about ketamine. *Am J Psychiatry* 2014; 171(3): 262-264.
296. Turner CA, Thompson RC, Bunney WE, Schatzberg AF, Barchas JD, Myers RM, et al. Altered choroid plexus gene expression in major depressive disorder. *Frontiers in Human Neuroscience* 2014; 8: 238.
297. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. *J Clin Psychiatry* 2014; 75(12): 1411-1418.
298. Yuen KW, Garner JP, Carson DS, Keller J, Lembke A, Hyde SA, et al. Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. *J Psychiatric Research* 2014; 51: 30-36.
299. Lee MS, Kim YH, Park WS, Park OK, Kwon SH, Hong KS, Rhim H, Shim I, Morita K, Wong DL, Pate PD, Lyons DM, Schatzberg AF, Her S. Temporal variability of glucocorticoid receptor activity is functionally important for the therapeutic action of fluoxetine in the hippocampus. *Mol Psychiatry* 2014.
300. Ray A, Tennakoon T, Keller J, Sarginson JE, Ryan HS, Murphy GM, Lazzeroni LC, Trivedi MH, Kocsis JH, DeBattista C, Schatzberg AF. ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. *Pharmacogenomics J* 2014.
301. Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the

- hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. *The World Journal of Biological Psychiatry* 2015; 16(1):2-11.
302. Thompson DG, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett RM, et al. fMRI Activation During Executive Function Predicts Response to Cognitive Behavioral Therapy in Older, Depressed Adults. *Am J Ger Psychiatry* 2015; 23(1): 13-22.
303. Bunney BG, Li JZ, Walsh DM, Stein R, Vawter MP, Cartagena P, Barchas JD, Schatzberg AF, et al. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. *Mol Psychiatry* 2015; 20(1): 48-55.
304. Day CV, Rush A John, Harris AW, Boyce PM, Rekshan W, Etkin A, DeBattista C, Schatzberg AF, et al. Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report. *J Affect Disord* 2015; 174: 493-502.
305. Etkin A, Patenaude B, Song YJ, Usherwood T, Rekshan W, Schatzberg AF, et al. A Cognitive-Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. *Neuropsychopharmacology* 2015; 40(6): 1332-1342.
306. Oathes DJ, Patenaude B, Schatzberg AF, Etkin A. Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. *Biol Psychiatry* 2015; 77(4): 385-393.
307. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? *Neuropsychopharmacology* 2015; 40(2): 259-267.
308. Saveanu R, Etkin A, Duchemin AM, Goldstein-Piekarski A, Gyurak A, DeBattista C, Schatzberg AF, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. *J Psychiatr Res* 2015; 61: 1-12.
309. Sudheimer K, Keller J, Gomez R, Tennakoon L, Reiss A, Garrett A, Kenna H, O'Hara R, Schatzberg AF. Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. *Neuropsychopharmacology* 2015; 40(4): 849-860.
310. Thompson DG, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett RM, Holland JM, Reiser R, Rasgon N, Schatzberg AF, O'Hara RM. FMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. *Am J Geriatr Psychiatry* 2015; 23(1): 13-22.
311. Schatzberg AF. The chicken and egg of anxiety and depression. *Epidemiology and Psychiatric Sciences* 2015; 24: 227-229. Commentary on Kessler RC, et al. *Epidemiology and Psychiatric Sciences* 2015; 24: 210-226.

312. Schatzberg AF, DeBattista C, Lazzeroni LL, Etkin A, Murphy Jr. G, Williams, L. ABCB1 Genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. *Am J Psychiatry* 2015; 172(8): 751-759.

Original Reports (Proceedings)

1. Schildkraut JJ, Orsulak PJ, Gudeman JE, Schatzberg AF, Rohde WA, LaBrie RA, Cahill JF, Cole JO, Frazier SH. Recent studies of the role of catecholamines in the pathophysiology and classification of depressive disorders. In: Usdin E, Hamburg DA, Barchas JD, eds. *Neuroregulators and psychiatric disorders*. New York: Oxford University Press. 1977:122-128.

2. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Gudeman JE, Cole JO, LaBrie RA, Rohde WA. Biochemical discrimination of subtypes of depressive disorders. In: Usdin E, Kopin IJ, Barchas J, eds. *Catecholamines: Basic and clinical frontiers, Volume 2. Fourth International Catecholamine Symposium*. New York: Pergamon Press. 1979:1860-1862.

3. Schatzberg AF, Altesman RI, Cole JO. An update of the use of benzodiazepines in depressed patients. In: Usdin E, Skolnik P, Tallman JF, Greenblatt D, Paul SM, eds. *Pharmacology of Benzodiazepines*. London: Macmillan. 1982:45-51.

4. Schatzberg AF, Orsulak PJ, Rosenbaum AH, Cole JO, Schildkraut JJ. Biochemical subtypes of unipolar depressions. In: Clayton PJ, Barrett J, eds. *Treatment of depression: Old controversies and new approaches*. New York: Raven Press. 1983.

5. Schildkraut JJ, Schatzberg AF, Orsulak PJ, Mooney JJ, Rosenbaum AH, Gudeman JE. Biological discrimination of subtypes of depressions. In: Davis J, Maas J, eds. *The affective disorders*. Washington, DC: Am Psych Press. 1983:31-51.

6. Schatzberg AF, Cole JO, Cohen BM, Altesman RI, Sniffin CM. Survey of depressed patients who have failed to respond to treatment. In: Davis J, Maas J, eds. *The affective disorders*. Washington, DC: Am Psych Press. 1983:73-85.

7. Schatzberg AF, Cole JO, Elliott GR, Duffy FH. Application of advanced neurophysiological techniques to the diagnosis of atypical and refractory psychiatric patients. In: *The spectrum of antidepressant effect: Proceedings, VII World Congress of Psychiatry, Vienna, Austria, July 15, 1983*. Princeton: Excerpta Medica. 1984:55-86.

8. Oxaprotiline Study Group. A double-blind comparative trial of oxaprotiline with amitriptyline and placebo in outpatients with moderate depression: Relationship of urinary MHPG levels. In: Usdin E, Goldstein M, eds. *Frontiers in biochemical and pharmacological research in depression*. New York: Raven Press. 1984.

9. Schildkraut JJ, Schatzberg AF, Mooney JJ, Samson JA, Cole JO, Gerson B. Toward a biochemical classification of depressive disorders: Differential responses to treatment. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM, eds. *Proceedings of the IVth World Congress of Biological Psychiatry, Philadelphia, Pennsylvania, September 1985*. Amsterdam: Elsevier. 1986:16-18.

10. Rothschild AJ, Schatzberg AF, Langlais PJ. Corticosteroid/dopamine interactions in psychotic and nonpsychotic depressed patients. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM, eds. *Biological Psychiatry 1985: Proceedings of the IVth World Congress of Biological Psychiatry*, Philadelphia, Pennsylvania, September 1985. Amsterdam: Elsevier. 1986:714-716.
11. Bond TC, Rothschild AJ, Lerbinger JE, Schatzberg AF. DST ranges and delusional depression. In: Shagass C, Josiassen RC, Bridger WH, Weiss J, Stoff D, Simpson GM, eds. *Biological Psychiatry 1985: Proceedings of the IVth World Congress of Biological Psychiatry*, Philadelphia, Pennsylvania, September 1985. Amsterdam: Elsevier. 1986:711-713.
12. Schatzberg AF, Cole JO, Elliott GR. Recent studies on treatment resistant depression. In: Halbreich U, Feinberg SS, eds. *Psychosocial aspects of nonresponse to antidepressant drugs*. Washington, DC: Am Psych Press. 1986:93-109.
13. Schatzberg AF, Samson JA, Bloomindale KL, Orsulak PJ, Gerson B, Cole JO, Schildkraut JJ. Urinary catecholamines, metabolites and D-type scores in subtypes of depressive disorders. In: Belmaker RH, Sandler M, Dahlstrom A, eds. *Progress in Catecholamine Research, Part C: Clinical Aspects. Proceedings of the VI International Catecholamine Symposium*. New York: Alan B. Liss. 1988:223-229.
14. Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in (delusional) psychotic depression. *Ann New York Acad Sci*. 1988;(537)462-471.
15. Schatzberg AF. Anxiety and adjustment disorder. *J Clin Psychiatry*. 1990; 51(Suppl 11):20-24.
16. Schatzberg AF. Triazolobenzodiazepines in the treatment of depressive disorders. In: Leonard B, ed. *Proceedings of British Association for Psychopharmacology - "Antidepressants: Thirty Years On."* London: CNS Publishers. 1991:311-319.
17. Nierenberg AA, Keck PE, Jr, Samson J, Rothschild AJ, Schatzberg AF. Methodologic considerations for the study of treatment resistant depression. In: Amsterdam JD, ed. *Refractory depression*. New York: Raven Press. 1991:1-12.
18. Schatzberg AF, Ballenger JC. Decisions for the clinician in the treatment of panic disorder: When to treat, which treatment to use, and how long to treat. *J Clin Psychiatry*. 1991; 52(Suppl 2):26-31.
19. Schatzberg AF. Dosing strategies for antidepressant agents. *J Clin Psychiatry*. 1991; 52(Suppl 5):14-20.
20. Schatzberg AF. Overview of anxiety disorders: Prevalence, biology, course, and treatment. *J Clin Psychiatry*. 1991; 52(Suppl 7):5-9.
21. Schatzberg AF, Posener JA. Benzodiazepines in the treatment of depressive disorders: An updated review. In: *Biological Psychiatry, v.1. Proceedings of the 5th*

World Congress of Biological Psychiatry. Racagni G, Brunello N, Fukuda T., eds. Amsterdam: Elsevier. 1991:318-321.

22. Schatzberg AF, Posener JA, Rothschild AF. Effects of dexamethasone, adrenocorticotrophic hormone and corticotrophin releasing hormone on dopamine activity in man. In *Biological Psychiatry*, v2. Proceedings of the 5th World Congress of Biological Psychiatry. Racagni G, Brunello N, Fukuda T. eds. Amsterdam: Elsevier. 1991:559-562.

23. Schatzberg AF. Recent developments in the acute somatic treatment of major depression. *J Clin Psychiatry*. 1992; 53(Suppl 3):20-25.

24. Schildkraut JJ, Schatzberg AF, Samson JA, Rosenbaum A, Bowden CL: Norepinephrine output and metabolism in depressed patients during antidepressant treatments. Proceedings of the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress, Nice, France, 1992. *Clin Neuropharm*. 1992; 15(Suppl 1A): 323A-324A.

25. Schatzberg AF, Rothschild AJ. Serotonin activity in psychotic (delusional) major depression. *J Clin Psychiatry*. 1992; 53(Suppl 10):52-55.

26. Schatzberg AF, Posener JA, Rothschild AJ: The role of dopamine in psychotic depression. Proceedings of an international Conference on Dopamine in Neurological and Psychiatric Disorders. Kalamazoo, Michigan. 1994; *Clin Neuropharm*. 1995, 18(Suppl 1):66-73.

27. Schatzberg AF. Initial treatment. *American Society of Clinical Psychopharm - Progress Notes - 1995-96*; 6:16-21.

28. Schatzberg AF. Course of depression in adults: treatment options. *Psychiatric Annals*. 1996; 26:336-341.

29. Levine S, Lyons DM, Schatzberg AF. Psychobiological consequences of social relationships. *Annals of the New York Academy of Sciences*. 1997; 807:210-218.

30. Schatzberg AF. Introduction. The role of noradrenaline in depression: New therapeutic options. Proceedings of the ECNP satellite symposium. *European Neuropsychopharm*. 1997; 7(Suppl 1):S1-S2.

31. Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. *Depression and Anxiety*. 1996/1997; 4:182-189.

32. Schatzberg AF. Introduction: The dynamics of sex: Gender differences in psychiatric disorders. *J Clin Psychiatry*. 1997; 58(Suppl 15):3-4.

33. Schatzberg AF. Perennial issues in the management of depression. Proceedings of a symposium. Symposium moderator. *Current Therapeutics Inc. SSI, Beachwood, OH*. 1998.

34. Schatzberg AF. Bipolar disorder: Recent issues in diagnosis and classification. *J Clin Psychiatry*. 1998; 59(Suppl 6):5-10.
35. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: Predictors of treatment response. *J Clin Psychiatry*. 1998; 59(Suppl 14):15-18.
36. Montgomery SA, and Schatzberg AF. Introduction: Reboxetine: A new selective antidepressant for the treatment of depression. *J Clin Psychiatry*. 1998; 59(Suppl 14):3.
37. Schatzberg AF. Bipolar disorder: Recent issues in diagnosis and classification. *J Clin Psychiatry*. 1998; 59 (Suppl 6):5-10.
38. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. *J Clin Psychiatry*. 1999; 60(Suppl 4):14-21.
39. Schatzberg AF. Phenomenology and Treatment of Agitation. *J Clin Psychiatry Monograph Series*. 1999; 17:2-12-14.
40. Schatzberg, AF. Clinical efficacy of reboxetine in major depression. *J Clin Psychiatry*. 2000; 61(Suppl 10) 31-38.
41. Schatzberg AF. New indications for antidepressants. *J Clin Psychiatry*. 2000; 61(Suppl 11) 9-17.
42. Schatzberg AF. Pharmacological principles of antidepressant efficacy. *Hum Psychopharmacol*. 2002; 17 Suppl 1:S17-22.
43. Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. *J Clin Psychiatry*. 2002; 63 Supp 1:18-31.
44. Sommer BR, Schatzberg AF. Ginkgo biloba and related compounds in Alzheimer Disease. *Psychiatric Annuals*. 2002; 32(1):13-18.
45. Schatzberg AF. Achieving full remission: resolving physical and emotional symptoms. *Mental Fitness*. 2003; 2 Suppl 1:14-19.
46. Schatzberg AF. New approaches to managing psychotic depression. *J Clin Psychiatry* 2003; 64 Suppl 1:19-23.
47. Schatzberg AF. Introduction: treating depression and anxiety to remission. *J Clin Psychiatry* 2003; 64 Suppl 15:3-4.
48. Schatzberg AF. Introduction: recent developments in achieving depression remission. *J Clin Psychiatry* 2003; Suppl 13:4.
49. Schatzberg AF. Non-schizophrenic psychoses: common and distinguishing features. *J Psychiatr Res*. 2004 Jan-Feb 38(1):1-2.

50. Schatzberg AF. Recent studies of the biology and treatment of depression. *Focus* 2005; Vol III (1): 14-24.
51. Schatzberg, AF, Weiss, RD, Brady, KT, Culpepper, L (2008) Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. *CNS Spectr* 2008; 13 (4 Suppl 6): 3.
52. Schatzberg, AF (2008) Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. *CNS Spectr*, 13(4 Suppl 6): 10-12.

Letters to the Editor and Invited Editorials

1. Schatzberg AF, Cole JO. Reply to Scholomskas JJ: Speech blockage in young patients taking tricyclics. *Am J Psychiatry*. 1978; 135:1573.
2. Schatzberg AF. Reply to Schnee J: Speech blockage, therapeutic side effect: *Am J Psychiatry*. 1978; 135:1246.
3. Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, McLaughlin RA, Sullivan MA, Cole JO. Reply to Clower OG: DST, identification of subtypes of depression. *Am J Psychiatry*. 1983; 140:88-91.
4. Rosenbaum AH, Schatzberg AF. Reply to Berger M: Physostigmine's influence on DST results. *Am J Psychiatry*. 1984; 141:470.
5. Rothschild AJ, Schatzberg AF. Postdexamethasone cortisol levels and subgroups of affective illness. *Arch Gen Psychiatry*. 1985; 42:732.
6. Teicher MH, Altesman RI, Cole JO, Schatzberg AF. Possible nephrotoxic interaction of lithium and metronidazole. *JAMA*. 1987; 254:3365-3366.
7. Rothschild AJ, Schatzberg AF. Theoretical basis for response to steroid suppression in major depression. *J Clin Psychopharmacology*. 1992; 12:142-143.
8. Schatzberg AF, Rothschild AJ. Reply to Fink M. *Am J Psychiatry*. 1993; 150:1131.
9. DeBattista C, Schatzberg AF. Treatment of psychotic depression. *Am J Psychiatry*. 1997; 154:1625-1626.
10. Schatzberg AF. Antidepressant discontinuation syndrome: update on SSRIs. *J Clin Psychiatry*. 1998; 59:536-537.
11. DeBattista C, Solvason HB, Heilig Breen, JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. *J Clin Psychopharmacol*. 2000; 20:274-275.
12. Schatzberg AF. Pros and cons of Prozac and its relatives. (Invited Editorial.) *Am J Psychiatry*. 2000; 157:3 323-325.

13. Schatzberg AF. Reply to Lara and Souza: Should We Keep Calling Antidepressants Antidepressants? *J Clin Psychiatry*. 2001; 829-830.
14. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Keller MB. Dr. Kornstein and Colleagues Reply. *Am J of Psychiatry*. 2001; 159:1532-1533.
15. Schatzberg AF. Brain imaging in affective disorders: more questions about causes versus effects. (Invited Editorial.) *Am J Psychiatry*. 2002; 159:1807-1808.
16. Schatzberg AF. Major depression: Causes or effects? (Invited Editorial.) *Am J Psychiatry*. 2002; 159:1077-1079.
17. Ohayon, M, Schatzberg AF. Fine-tuning our diagnosis and treatment of depression. *J Psychiatric Research*. 2006, 40: 281-282.
18. Krystal JH, Carter CS, Geschwind D, Manji HK, et al: It is time to take a stand for medical research and against terrorism targeting medical scientists. *Biol Psychiatry* 2008; 63(8): 725-727.
19. Schatzberg, AF (2009) The silver lining of recent effectiveness trials. *World Psychiatry*, 8(1): 30-32.

Reviews (Chapters)

1. Schatzberg AF. Book review of Robert J. Lifton, ed. *Explorations in psychohistory: The wellfleet papers*. *Am J Psychotherapy*. 1976; 30:331-332.
2. Schildkraut JJ, Orsulak PJ, Gudeman JE, Schatzberg AF, Rohde WA, LaBrie RA, Cahill JF, Cole JO, Frazier SH. Norepinephrine metabolism in subtypes of depressive disorders. In: Shagass C, Gershon S, Friedhoff AJ, eds. *Psychopathology and brain dysfunction*. New York: Raven Press. 1977; 125-138.
3. Schatzberg AF. Classification of depressive disorders. In: Cole JO, Schatzberg AF, Frazier SH, eds. *Depression: Biology, psychodynamics and treatment*. New York: Plenum Press. 1978; 13-40.
4. Isenberg P, Schatzberg AF. Psychoanalytic contribution to a theory of depression. In: Cole JO, Schatzberg AF, Frazier SH, eds. *Depression: Biology, psychodynamics and treatment*. New York: Plenum Press. 1978; 149-171.
5. Schildkraut JJ, Orsulak PJ, Gudeman JE, Schatzberg AF, Rohde WA, LaBrie RA, Cahill JF, Cole JO, Frazier SH. Norepinephrine metabolism in depressive disorders: Implications for a biochemical classification of depression. In: Cole JO, Schatzberg AF, Frazier SH, eds. *Depression: Biology, psychodynamics and treatment*. New York: Plenum Press. 1978; 75-101.
6. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Herzog JM, Gudeman JE, Cole JO, Rohde WA, LaBrie RA. Biochemical discrimination of subgroups of affective and

- schizophrenic disorders. In: Fielding S, Effland RC, eds. *New frontiers in psychotropic drug research*. Mount Kisco: Futura. 1979; 1-27.
7. Schatzberg AF. MHPG for discriminating among subtypes of unipolar depressions and predicting response to maprotiline. *Int Drug Ther Newsletter*. No 8. 1980; 15:29-31.
 8. Schatzberg AF, Cole JO, Rosenbaum AH, Maruta T, Orsulak PJ, Schildkraut JJ. The use of maprotiline in testing MHPG predictive hypotheses. In: Flach FF (Chairman): *New dimensions in antidepressants: Ludiomil (maprotiline HCL)*. Princeton: Excerpta Medica, 1981; 76-80.
 9. Schatzberg AF. Commentary on chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of the antidepressant maprotiline hydrochloride. *Pharmacotherapy*. 1981; 1:139.
 10. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Cole JO, Rosenbaum AH. Biochemical discrimination of subgroups of depressive disorders based on differences in catecholamine metabolism. In: Usdin E, Hanin I, eds. *Biological markers in psychiatry and neurology*. New York: Pergamon Press. 1982; 23-33.
 11. Cole JO, Schatzberg AF. Antidepressant drugs. In: Cavenar JO, Jr, Brodie HKH, eds. *Critical problems in psychiatry*. Philadelphia: J.B. Lippincott. 1982; 115-127.
 12. Schatzberg AF, Cole JO. Basic pharmacology and clinical effects of antidepressants. *Family Practice Report*. 1983; (Suppl 5):7-15.
 13. Schatzberg AF. The clinical laboratory and psychiatric practice. *Medicine & Psychiatry*. 1983; 1:1.
 14. Schatzberg AF. The dexamethasone suppression test. *Medicine & Psychiatry*. 1983; 1:2.
 15. Schatzberg AF. Ictal phenomena and affective disorders. *Medicine & Psychiatry*. 1983; 1:5.
 16. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Rosenbaum AH. Relationship between psychiatric diagnostic groups of depressive disorders and MHPG. In: Maas JW, ed. *MHPG and psychopathology*. New York: Academic Press. 1983; 129-144.
 17. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Mooney JJ, Rosenbaum AH, Gudeman JE, Cole JO. Laboratory tests for discriminating subtypes of depressive disorders based on measurements of catecholamine metabolism. In: Zales MR, ed. *Affective and schizophrenic disorders: New approaches to diagnosis and treatment*. New York: Bruner/Mazel. 1983; 103-123.
 18. Cole JO, Schatzberg AF. Antidepressant drug therapy. In: Grinspoon L, ed. *Psychiatry Update Vol. II*. The Am Psych Press. 1983; 472-491; 542-544.

19. Schatzberg AF, Elliott GR. Discussion of Stone, MH: Critical and unresolved issues of borderline personality. *Integrative Psychiatry*. 1984; 2:5.
20. Schatzberg AF. Commentary on the pharmacology of buspirone. *Pharmacotherapy*. 1984; 4:324.
21. Schatzberg AF. The DST in the elderly. *Medicine & Psychiatry*. 1984; 1:3.
22. Schatzberg AF. Monitoring patients on antidepressants. *Medicine & Psychiatry*. 1984; 1:7.
23. Schatzberg AF. Length of treatment for depression. *Medicine & Psychiatry*. 1984; 1:10-11.
24. Schatzberg AF. A review of the psychopharmacology of anxiety disorders. *Family Practice Recert*. 1984; (Suppl 6):35-42.
25. Schatzberg AF. Evaluation and treatment of the refractory depressed patient. In: Bernstein JG, ed. *Clin psychopharm*. 2nd Ed. Littleton: Writ. PSG, 1984; 77-92.
26. Schildkraut JJ, Orsulak PJ, Schatzberg AF, Rosenbaum AH. Urinary MHPG in affective disorders. In: Post RM, Ballenger JC, eds. *The neurobiology of mood disorders*. Baltimore: Williams & Wilkins Company. 1984; 519-528.
27. Orsulak PJ, Schatzberg AF, Grab EL, Schildkraut JJ. Urinary MHPG levels as predictors of response to the antidepressant maprotiline. In: Moyer TP, Boeck RL, eds. *Applied therapeutic drug monitoring. Vol. II: Review and case studies*. Washington, DC: Am Assoc for Clin Chemistry. 1984; 259-263.
28. Schatzberg AF. Clinical diagnosis and classification of affective disorders. In: Habig RL, ed. *The brain, biochemistry, and behavior: The VIth Beckman Conference*. Washington, DC. Am Assoc for Clin Chemistry. 1984; 29-46.
29. Schildkraut JJ, Schatzberg AF, Orsulak PJ, Rosenbaum AH, Cole JO. Toward a biochemical classification of depressive disorders and the emerging field of psychiatric chemistry. In: Habig RL, ed. *The brain, biochemistry and behavior: The VIth Beckman Conference*. Washington, DC: Am Assoc for Clin Chemistry. 1984; 47-64.
30. Schatzberg AF, Cole JO. Biochemical and pharmacologic properties of maprotiline: A selective norepinephrine uptake inhibitor. *J Clin Psychiatry Monograph Series*. 1984; 5:7-11.
31. Schatzberg AF. Endocrine abnormalities and psychiatric symptoms. *Medicine & Psychiatry*. 1984/1984; 2:6.
32. Schatzberg AF. Epidemiology of drug abuse/dependence. *Medicine & Psychiatry*. 1985; 2:5.
33. Schatzberg AF. Psychiatric sequelae of surgery: Recent studies on hysterectomy. *Medicine & Psychiatry*. 1985; 2:7.

34. Schatzberg AF, Elliott GR, Lerbinger JE, Marcel B, Duffy FH. Topographic mapping in depressed patients. In: Duffy FH, ed. Topographic mapping of brain electrical activity. Boston: Butterworths. 1986; 389-393.
35. Schatzberg AF. Bipolar illness. In: The AFP family practice annual. Missouri: American Academy of Family Physicians. 1986; 43-56.
36. Schatzberg AF. Commentary on Tyrer P. New rows of neuroses - are they an illusion? Integrative Psychiatry. 1986; 4:30-31.
37. Schatzberg AF. New antidepressants. The Harvard Medical School Mental Health Letter. 1987; 4:8.
38. Rothschild AJ, Schatzberg AF. Biochemical and neuroendocrine studies in psychotic and nonpsychotic depressions. In: Schatzberg AF, Nemeroff CB, eds. Physiology and pathophysiology of the HPA axis: Psychiatric implications. New York: Raven Press. 1988; 187-200.
39. Schatzberg AF. Psychopharmacologic treatment of depression. In: Shader RI, Tupin J, Harnett DS, eds. Handbook of clin psychopharmacology. Second Edition. New York: Raven Press. 1988; 49-71.
40. Schatzberg AF. New treatment for anxiety: Update on buspirone. Harvard Medical School Mental Health Letter. 1988; 4:8.
41. Schatzberg AF. Fluoxetine. Harvard Medical School Mental Health Letter. 1989; 5:9.
42. Schatzberg AF, Sheehan DV, Lerbinger J. Biological discrimination between anxiety and depression. In: Ballenger JC, ed. Neurobiological aspects of panic disorders. New York: Alan R. Liss, Inc. 1990; 321-330.
43. Goldblatt MJ, Schatzberg AF. Somatic treatment of the adult suicidal patient. In: Blumenthal SJ, Kupfer DJ, eds. Suicide over the life cycle: A comprehensive guide to risk factors, assessment, and treatment. Washington, DC: Am Psych Press, Inc. 1990; 425-440.
44. Goldblatt MJ, Schatzberg AF. Medication and the suicidal patient. In: Jacobs D, ed. Suicide and clinical practice: Multiple perspectives. Washington, DC: Am Psych Press, Inc. 1992; 23-41.
45. Schatzberg AF. Future psycho pharmacology for the aging patient: Treatment of Alzheimer's Disease. In: Dunner DL ed. Current Psychiatric Therapy. Orlando, W. B. Saunders. 1992; 551-555.
46. Rothschild AJ, Schatzberg AF. Psychotic Depression. A newly recognized subtype. Clin Neurosciences. 1993. 1:75-80.

47. Nathan K, Schatzberg AF. Biological markers in mood disorders. In: Oldham JM, Riba MB eds. *Review of Psychiatry - Vol. 13*. Washington, Am Psych Press. 1994; 171-186.
48. Rothschild AJ, Schatzberg AF. Diagnosis and treatment of psychotic (delusional) depression. In: Grunhaus L, Greden JF, eds. *Severe Depressive Disorders*. Washington: Am Psych Press. 1994; 195-207.
49. Hirschfeld RMA, Schatzberg AFS. Long-term management of depression. *Am J of Medicine*. 1994; 97(Suppl 6A):33S-38S.
50. Schatzberg AF, Schildkraut JJ. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ, eds. *Psychopharmacology: The Fourth Generation of Progress*. Raven Press. 1995; 911-920.
51. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. In: *Treating comorbid anxiety and depression: Monograph Series*. J Clin Psychiatry. 1995; 13:2-12.
52. DeBattista C, Schatzberg AF. Somatic therapy. In: Glick I, Yalom I eds. *Treating depression*. San Francisco: Jossey-Bass, Inc. 1995; 153-172.
53. Schatzberg AF. Fluoxetine. In: Kaplan HI, Sadock BJ. *Comprehensive Textbook of Psychiatry*. VI Edition. Baltimore: Williams and Wilkins. 1996; 2056-2063.
54. Barry JJ, Schatzberg AF. Trazodone and nefazodone. In: Kaplan HI, Sadock BJ. *Comprehensive textbook of psychiatry*. VI Edition. Baltimore: Williams and Wilkins. 1996; 2089-2096.
55. DeBattista C, Schatzberg AF. Paroxetine. In: Kaplan HI, Sadock BJ. *Comprehensive textbook of psychiatry*. VI Edition. Baltimore: Williams and Wilkins. 1996; 2063-2069.
56. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? In: Widiger TA, Frances AF, Pincus HA et al, eds. *DSM-IV Source Book*. Volume 2; Washington: Am Psych Press. 1996; 127-179.
57. DeBattista C, Schatzberg AF. New options in pharmacotherapy for geriatric depression: Limiting side effects and drug interactions. In: Schwenker G, ed. *Clin Geriatrics*. Multi Mediahealth Care. 1996; 4:8.
58. Nemeroff CB, Musselman DL, Nathan KI, Schatzberg AF, Knable MB, Kleinman JE, Weinberger DR, Kilts CD, Weiss JM. Pathophysiological basis of psychiatric disorders: Focus on mood disorders and schizophrenia. In: Tasman A, Kay J, Lieberman JA eds. *Psychiatry*. Volume 1; W. B. Saunders Company. 1997; 258-311.
59. Nemeroff CB, Schatzberg AF. Pharmacological treatment of unipolar depression. In: Nathan PE, Gorman JM, eds. *A Guide to Treatments that Work*. New York: Oxford University Press. 1998; 212-225.

60. DeBattista C, Solvason HB, Schatzberg AF. Mood disorders. In: Encyclopedia of Mental Health, Vol. 2 pp. 721-732. Academic Press. 1998.
61. Musselman DL, DeBattista C, Nathan KI, Kilts CD, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff, (Eds). Textbook of Psychopharmacology: 2nd Edition. Washington, DC: Am Psych Press. 1998; 549-588.
62. Goldblatt MJ, Schatzberg AF, Silverman MM. Psychopharmacological treatment of suicidal inpatients: Medical and legal issues. In: Bongar B, Berman AL, Maris R, Silverman M, Harris EA, Packman W, (Eds.) Risk Management with Suicidal Patients. New York: Guilford. 1998; 110-129.
63. Belanoff JK, DeBattista C, Schatzberg AF. Adult psychopharmacology. In: Koocher CP, Norcoross JC, Hill SS III, (Eds.). Psychologists Desk Reference. Washington DC: American Psychological Association. 1998; 395-400.
64. DeBattista C, Solvason HB, Nelson C, Schatzberg AF. Major depression and its subtypes. In: Fawcett J, Stein DJ, Jobson KO, eds. Textbook of Treatment Algorithms in Psychopharmacology. John Wiley & Sons, Ltd. 1999.
65. DeBattista C, Smith DL, Schatzberg AF. Psychopharmacology of depression. In: Depression; Key Diseases Series American College of Physicians. 1999.
66. Schatzberg AF. Psychopharmacology in the new millennium, emphasis on depression. In: Weissman S, Sabshin M, Eist H, eds. Psychiatry in the New Millennium. Washington: Am Psych Press. 1999; 179-192.
67. DeBattista C, Smith DL, Schatzberg AF. Modulation of monoamine neurotransmitters by estrogen: Clinical implication. In: Leibenluft E, ed. Gender Differences in Mood and Anxiety Disorders, From Bench to Bedside. Review of Psychiatry, 18:3. Washington, DC: Am Psych Press. 1999; 137-160.
68. Levin S, Lyons DM, Schatzberg AF. Psychobiological consequences of social relationships. In: Carter CS, Lederhendler II, Kirkpatrick B, eds. The Integrative Neurobiology of Affiliation. Cambridge: MIT Press. 1999; 83-91.
69. Schatzberg AF, Kasper SF. Future directions in novel antidepressants and mood stabilizing agents. In: Buckley PF, Waddington JL, eds. Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann. 1999; 212-219.
70. Schatzberg AF, Kornstein. Gender and antidepressant response. In: Maj M, Sartorius N, eds. Depressive Disorders. New York: John Wiley and Sons, Ltd. 1999.
71. Berman RB, Belanoff JK, Charney DS, Schatzberg AF. Principles of the Pharmacotherapy of Depression. In: Charney D, Nestler EJ, Bunney BS, eds. Neurobiological Foundation of Mental Illness. New York: Oxford University Press. 1999; 419-432.

72. Mack JE, Schatzberg AF. Heroin use as an attempt to cope. In: Levin JD, ed. *Treating Addiction as a Human Process*. Jason Aronson Inc. 1999; 17-30.
73. DeBattista C, Smith DL, Schatzberg AF. Modulation of monoamine neurotransmitters by estrogen: Clinical implications. In: Leibenluft E, ed. *Gender Differences in Mood and Anxiety Disorders*. American Psychiatric Press, Inc. 1999; 137-160.
74. DeBattista C, Schatzberg AF. Other biological and pharmacological therapies. In: Kaplan HI, Sadock BJ, eds. *Comprehensive Textbook of Psychiatry, 7th Edition*. Baltimore: Williams and Williams. 2000; 2521-2531.
75. DeBattista C, Belanoff JK, Schatzberg AF. Treatment of Psychotic Depression. In: Halbreich U, Montgomery SA, eds. *Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders*. American Psychiatric Press, Inc. 2000; 305-313.
76. DeBattista C, Smith DL, Schatzberg AF. Psychopharmacology. In: Levenson JL, ed. *Depression*. Philadelphia: American College of Physicians–American Society of Internal Medicine. 2000; 97-122.
77. Cameron RP, Schatzberg AF. Mixed anxiety-depressive disorder. In: Stein DJ, Hollander E, eds. *Textbook of Anxiety Disorders*. Washington, DC: Am Psych Press. 2002; 159-170.
78. Schatzberg AF, Garlow SJ, Nemeroff CB. Molecular and cellular mechanisms in depression. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB, eds. *Neuropsychopharmacology: The Fifth Generation of Progress*. Philadelphia: Lippincott Williams & Wilkins. 2002; 1039-1050.
79. Nemeroff CB, Schatzberg AF. Pharmacological treatment of unipolar depression. In: Nathan PE, Gorman JM, eds. *A Guide to Treatments that Work*. New York: Oxford University Press. 2nd Edition. 2002; 229-244.
80. Lindley SE, Schatzberg AF. Historical roots of psychoneuroendocrinology. In: Wolkowitz OM, Rothschild AJ, eds. *Psychoneuroendocrinology: The Scientific Basis of Clinical Practice*. Arlington, VA: American Psychiatric Publishing, Inc. 2003; 9-25.
81. Kasper S, Schatzberg AF. Development of new treatment options for depression. In: Kasper S, den Boer JA, Ad Sitsen JM eds. *Handbook of Depression and Anxiety*. 2nd Edition. New York: Marcel Dekker, Inc. 2003.
82. DeBattista C, Schatzberg AF. Drug augmentation. In: Kaplan V and Kaplan S eds. *Comprehensive Textbook of Psychiatry*. 8th Edition. Baltimore: Williams and Wilkins. 2004; 3003-3008.
83. Flores BH, Musselman DL, DeBattista C, Garlow SJ, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology*. 3rd Edition. Washington, DC: Am Psych Press, Inc. 2004; 717-763.

84. Keller J, Buckley TM, Schatzberg, AF. Hypothalamic-Pituitary-Adrenal axis activity in mood and cognition in the elderly: implications for symptoms and outcomes. In: Roose S and Sackeim HA, eds. *Late-Life Depression*. New York: Oxford University Press. 2004; 157-166.
85. Flores BH, Schatzberg AF. Psychotic depression. In: Stein DJ, Kupfer DJ, Schatzberg AF. *Textbook of Mood Disorders*. Washington, DC: Am Psych Press. 2006; 561-571.
86. Nemeroff CB, Schatzberg AF. Pharmacological treatment of unipolar depression. In: Nathan PE, Gorman JM, eds. *A Guide to Treatments that Work*. 3rd Edition. New York: Oxford University Press. 2007; 271-284.
87. Kraemer HC, Schatzberg AF. Statistics, placebo response, and clinical trials design in psychopharmacology. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*, 4th Edition. Washington, DC: American Psychiatric Publishing, Inc., 2009; 243-258.
88. Schatzberg AF. Mirtazapine. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*, 4th Edition. Washington, DC: American Psychiatric Publishing, Inc., 2009; 429-437.
89. Gillespie C, Garlow SJ, Binder EB, Schatzberg AF, Nemeroff CB. Neurobiology of mood disorders. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*, 4th Edition. Washington, DC: American Psychiatric Publishing, Inc., 2009; 903-944.
90. Schatzberg AF. Chronic pain and depression. In: Mayer EA, Bushnell MC, eds. *Functional Pain Syndromes: Presentation and Pathophysiology*. Seattle, WA: IASP Press, 2009; 215-226.
91. Schatzberg AF. Psychiatric disorders. In: Robertson D, Williams GH. *Clinical and Translational Science: Principles of Human Research*. San Diego, CA: Academic Press, 2009; 461-475.
92. Schatzberg, AF. An applied context for personalized medicine in psychiatry. In: Gordon E, Koslow SH, eds. *Integrative Neuroscience and Personalized Medicine*. New York, NY: Oxford University Press, 2011; 17-24.
93. Blasey C, Belanoff JK, DeBattista C, Schatzberg AF. Adult Psychopharmacology. In: Koocher GP, Norcross JC, Greene BA, eds. *Psychologists' Desk Reference*, Third Edition. New York, Oxford University Press, 2013; 441-454.

Books and Monographs

1. Cole JO, Schatzberg AF, Frazier SH, eds. *Depression: Biology, Psychodynamics and Treatment*. New York: Plenum Press, 1978.

2. Schatzberg AF, ed. *Common Treatment Problems in Depression*. Washington, DC: American Psychiatric Press, 1985.
3. Schatzberg AF, Cole JO. *Manual of Clinical Psychopharmacology*. Washington, DC: American Psychiatric Press, 1986.
4. Schatzberg AF. *Medical Consultant. The Pill Book of Anxiety and Depression*. New York: Bantam Press, 1986.
5. Schatzberg AF. *The Biology of Depression. Clinical Update Monograph*. Kalamazoo: Upjohn Pharmaceuticals, 1987.
6. Schatzberg AF, Nemeroff CB, eds. *Physiology and Pathophysiology of the HPA Axis: Psychiatric Implications*. New York: Raven Press, 1988.
7. Schatzberg AF, Cole JO. *Manual of Clinical Psychopharmacology, 2nd Edition*. Washington, DC: American Psychiatric Press, 1991.
8. Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology*. Washington, DC: American Psychiatric Press, 1995.
9. Schatzberg AF, Cole JO, DeBattista C. *Manual of Clinical Psychopharmacology, 3rd Edition*. Washington, DC: American Psychiatric Press, 1997.
10. Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology. 2nd Edition*. Washington, DC: American Psychiatric Press, 1998.
11. Schatzberg AF, DeBattista C, Overman GP, Ereshefsky L. *The 1998 Black Book of Psychotropic Dosing and Monitoring*. New York: MBL Communications, Inc, 1998.
12. DeBattista C, Schatzberg AF, Overman GP, Ereshefsky L. *The 1999 Black Book of Psychotropic Dosing and Monitoring*. New York: MBL Communications, Inc, 1999.
13. Nemeroff CB, Schatzberg AF, eds. *Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care. U.S. Edition*. Washington, DC: American Psychiatric Press, 1999.
14. Nemeroff CB, Schatzberg AF, eds: *Recognition and Treatment of Psychiatric Disorders: a Psychopharmacology Handbook for Primary Care. U.S. Edition*. Washington, DC: American Psychiatric Press, 1999.
15. Schatzberg AF, Nemeroff CB, eds: *Essentials of Clinical Psychopharmacology*. Washington, American Psychiatric Press, 2001.
16. Nemeroff CB, Schatzberg AF. *Diagnóstico y Tratamiento de los Trastornos Psiquiátricos: Manual de Psicofarmacología Para Atención Primaria*. Barcelona: Ars Medica, 2001.
17. Schatzberg AF, Nemeroff CB. *Psicofarmacologia 1*. Borgone: Centro Scientifico Editore, 2001.

18. Schatzberg AF, Nemeroff CB. *Psicofarmacologia 2*. Borgone: Centro Scientifico Editore, 2001.
19. Schatzberg AF, Nemeroff CB. *Fundamentos de Psicofarmacologia Clínica*. Rio de Janeiro: Editora Guanabara Koogan SA, 2002.
20. Schatzberg AF, Cole JO, DeBattista C. *Manual of Clinical Psychopharmacology*, 4th Edition. Washington, DC: American Psychiatric Press, 2003.
21. Schatzberg AF, Nemeroff CB. *Psicofarmacologia clinica*. Edizione Italiana a Cura di Giorgio Racagni. Milano: Masson S.p.A. 2003.
22. Schatzberg AF, Nemeroff CB, eds. *Textbook of Psychopharmacology*, 3rd Edition, Washington, DC: American Psychiatric Press, 2004.
23. Schatzberg AF, Cole JO, DeBattista CB. *Manual of Clinical Psychopharmacology*, 5th Edition, Washington, DC: American Psychiatric Press, 2005.
24. Stein DJ, Kupfer DJ, Schatzberg AF, eds. *Textbook of Mood Disorders*. Washington, DC: American Psychiatric Press, 2005.
25. Schatzberg AF, Nemeroff CB, eds. *Tratado de Psicofarmacología*, Barcelona, Spain: Masson, 2006.
26. Schatzberg AF, Nemeroff CB, eds: *Essentials of Clinical Psychopharmacology*, 2nd Edition. Washington, American Psychiatric Press, 2006.
27. Schatzberg AF, Nemeroff CB, eds. *Klinik Psikofarmakolojinin Esaslari*, Washington, DC: American Psychiatric Press, 2006.
28. Stein DJ, Kupfer DJ, Schatzberg AF, eds. *Textbook of Mood Disorders (I and II)*, Edición en Español. Barcelona, España: Medical Trends, 2006.
29. Schatzberg AF, Cole JO, DeBattista CB: *Manual of Clinical Psychopharmacology*, 6th Edition. Washington, DC: American Psychiatric Press, 2007.
30. Stein DJ, Kupfer DJ, Schatzberg AF, eds. *Duygudurum Bozukluklari*, Edition in Turkish. İİK Baski: Sigma Publishing, 2007.
31. Schatzberg AF, Cole JO, DeBattista CB. *Manuel de Psicofarmacologia Clínica*, 6th Edition in **Portuguese**, Porto Alegre: Artmed Editoria; 2009.
32. Schatzberg AF, Nemeroff CB: *Textbook of Psychopharmacology*, IV Edition. Washington, DC. American Psychiatric Press, 2009.
33. Hales RE, Shahrokh NC, Schatzberg AF, Nemeroff CB: *Study Guide to Psychopharmacology: A Companion to The American Psychiatric Publishing Textbook of Psychopharmacology*, Fourth Edition. Washington, DC. American Psychiatric Press, 2009.

34. Schatzberg AF, Cole JO, DeBattista CB: Manual of Clinical Psychopharmacology, 7th Edition. Washington, DC: American Psychiatric Press, 2010.
35. Schatzberg AF, Nemeroff CB, eds: Essentials of Clinical Psychopharmacology, 3rd Edition. Washington, American Psychiatric Press, 2013.

Non-Print Materials

1. Schatzberg AF. Overview and patient characteristics. In: So-called treatment resistant depression. (Audiocassette Program XVI of the Am Psych Assoc, 131st Annual Mtg, 1978). Washington: Am Psych Assoc, 1978.
2. Schatzberg AF. Affective disorders. In: Survey of psychiatry (audiocassette course). Washington: Am Psych Assoc/McLean Hospital, 1980.
3. Schatzberg AF. Moderator and course director, Am Medical Assoc Videoclinic, "The depressed patient" (1-hour videotape course). Chicago: Am Medical Assoc, 1981.
4. Schatzberg AF. The biology and treatment of affective disorders. In: The new psychiatry (audiocassette course). Belmont: McLean Hospital, Facility for Cont Ed, 1981.
5. Schatzberg AF. Affective disorder. Major depression. In: Interviewing techniques in psychiatry (audiocassette course). Belmont: McLean Hospital, Facility for Cont Ed, 1983.
6. Schatzberg AF. Moderator and course director, Am Medical Assoc Videoclinic, "The anxious patient" (2-hour videotape course). Chicago: Am Medical Assoc, 1983.
7. Schatzberg AF. The clinical diagnosis of affective disorders. In: The brain, biochemistry, and behavior: Slide and tape presentation. Washington, DC: Am Assoc for Clin Chemistry, 1984.
8. Schatzberg AF. Moderator, Am College of Psychiatrists Psychiatry Update - "Update on anxiolytic medications" (audiocassette program), 1986.
9. Schatzberg AF. Moderator. Displaced Americans: A report on clinical depression in an era of economic dislocation (videocassette program), New York: The Roering Psychiatry Video Library, 1988.
10. Schatzberg AF. Discussant, Am College of Psychiatrists Psychiatry Update - "Suicide across the life cycle: Research and clinical practice" (audiocassette program), 1989.
11. Schatzberg AF. Moderator, Am College of Psychiatrists Psychiatry Update: Update on selective serotonin reuptake inhibitors (audiocassette program), 1994.
12. Schatzberg AF. Moderator, Antidepressant discontinuation syndrome: An update on serotonin reuptake inhibitors. Lilly discontinuation audiotape transcript, 1997.
13. Schatzberg AF, Fava M, Rosenbaum FJ, Zajecka JM. Depression insights: SSRI interruption/discontinuation syndrome. J Clin Psychiatry, Audiograph Series. 2:5, 1998.

14. Schatzberg AF, Keller MB, Manning JS, Rush, Jr AJ. Depression insights: Diagnosis and treatment of major depression. J Clin Psychiatry, Audiograph Series. 2:7, 1998.
15. Schatzberg AF, Cohen LS, Casper R, Parry BL. Depression: managing depression and related disorders during a woman's life cycle. J Clin Psychiatry, Audiograph Series. 2:2, 1999.
16. Keck Jr. PE, Manning JS, Nelson CN, Schatzberg AF, Thase ET. New Approaches to managing difficult-to-treat depressions. J Clin Psychiatry, Audiograph Series. 5(8) 2002.

Alan F. Schatzberg
December 31, 2015

